This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are
presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.
"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.
Num | microRNA | Gene | miRNA log2FC | miRNA pvalue | Gene log2FC | Gene pvalue | Interaction | Correlation beta | Correlation P-value | PMID | Reported in cancer studies |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | hsa-let-7b-5p | AIFM1 | -0.19 | 0.65188 | 0.57 | 0.10576 | miRNATAP | -0.16 | 0.0007 | NA | |
2 | hsa-miR-125b-5p | AKT1 | -2.01 | 0.00516 | 0.11 | 0.66561 | miRNAWalker2 validate; miRTarBase | -0.05 | 0.00588 | NA | |
3 | hsa-miR-214-3p | AKT2 | -0.01 | 0.98584 | -0.09 | 0.77127 | mirMAP | -0.05 | 0.01027 | NA | |
4 | hsa-miR-106a-5p | AKT3 | 3.99 | 0 | -3.33 | 1.0E-5 | miRNATAP | -0.12 | 0.02117 | NA | |
5 | hsa-miR-106b-5p | AKT3 | 2.81 | 0 | -3.33 | 1.0E-5 | miRNATAP | -0.41 | 1.0E-5 | NA | |
6 | hsa-miR-142-3p | AKT3 | 4.35 | 0 | -3.33 | 1.0E-5 | miRanda | -0.16 | 0.00934 | NA | |
7 | hsa-miR-15a-5p | AKT3 | 2.05 | 0 | -3.33 | 1.0E-5 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.37 | 0.00021 | NA | |
8 | hsa-miR-15b-5p | AKT3 | 3.32 | 0 | -3.33 | 1.0E-5 | miRNATAP | -0.25 | 0.00571 | NA | |
9 | hsa-miR-16-5p | AKT3 | 2.94 | 0 | -3.33 | 1.0E-5 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.31 | 0.00086 | NA | |
10 | hsa-miR-17-5p | AKT3 | 2.33 | 2.0E-5 | -3.33 | 1.0E-5 | TargetScan; miRNATAP | -0.17 | 0.02914 | NA | |
11 | hsa-miR-20b-5p | AKT3 | 4.57 | 5.0E-5 | -3.33 | 1.0E-5 | miRNATAP | -0.09 | 0.01499 | NA | |
12 | hsa-miR-29b-2-5p | AKT3 | -0.6 | 0.18954 | -3.33 | 1.0E-5 | mirMAP | -0.23 | 0.01747 | NA | |
13 | hsa-miR-29b-3p | AKT3 | 0.67 | 0.23406 | -3.33 | 1.0E-5 | miRNATAP | -0.28 | 0.00031 | 26512921 | MicroRNA 29B mir 29b regulates the Warburg effect in ovarian cancer by targeting AKT2 and AKT3 |
14 | hsa-miR-3065-5p | AKT3 | 2.14 | 0.06094 | -3.33 | 1.0E-5 | mirMAP | -0.22 | 0 | NA | |
15 | hsa-miR-362-3p | AKT3 | 0.68 | 0.22615 | -3.33 | 1.0E-5 | miRanda | -0.25 | 0.00124 | NA | |
16 | hsa-miR-501-3p | AKT3 | 1.72 | 0.00759 | -3.33 | 1.0E-5 | miRNATAP | -0.18 | 0.00733 | NA | |
17 | hsa-miR-502-3p | AKT3 | -0.1 | 0.80889 | -3.33 | 1.0E-5 | miRNATAP | -0.23 | 0.03065 | NA | |
18 | hsa-miR-93-5p | AKT3 | 2.66 | 0 | -3.33 | 1.0E-5 | miRNATAP | -0.33 | 0.00021 | NA | |
19 | hsa-miR-155-5p | APAF1 | 2.81 | 7.0E-5 | 0.35 | 0.33131 | miRNAWalker2 validate | -0.11 | 0.0002 | 22996741; 26877850 | MiR 155 inhibits the sensitivity of lung cancer cells to cisplatin via negative regulation of Apaf 1 expression; The objective of this study is to verify the hypothesis based on the results of bioinformatics analysis that miR-155 modulates cellular apoptosis and DNA damage through the regulation of Apaf-1 and is thus involved in the development and progression of lung cancer; First we measured the expression of miR-155 and the Apaf-1 protein in lung cancer tissues; The results showed that expression of miR-155 was significantly higher in lung cancer tissues than in paracancerous and normal tissues; whereas Apaf-1 expression was lower in the lung cancerous tissues; The results showed that relative to controls the silencing of miR-155 resulted in elevated expression of the Apaf-1 protein whereas Apaf-1 mRNA levels remained unchanged; Both the silencing of miR-155 and the overexpression Apaf-1 greatly increased the sensitivity of A549 cells to cisplatin treatment as evidenced by elevated rates of apoptosis and DNA damage; Furthermore dual-transfection of A549 cells with miR-155 siRNA and Apaf-1 siRNA resulted in the attenuation of apoptosis and DNA damage;Also increase in the transcript level of APAF-1 and CASP-9 after downregulation of miR-21 and miR-155 might indicate that these genes were targeted by aforementioned miRNAs in T47D cells |
20 | hsa-miR-23a-3p | APAF1 | 0.93 | 0.01273 | 0.35 | 0.33131 | miRNATAP | -0.25 | 1.0E-5 | 24992592; 24249161 | Luciferase assay was performed to verify a putative target site of miR-23a in the 3'-UTR of apoptosis protease activating factor 1 APAF1 mRNA; The expression levels of miR-23a and APAF1 in CRC cell lines SW480 and SW620 and clinical samples were assessed using reverse transcription-quantitative real-time PCR RT-qPCR and Western blot; Moreover miR-23a up-regulation was coupled with APAF1 down-regulation in CRC tissue samples;We found that the expression of miR-23a was increased and the level of apoptosis-activating factor-1 APAF-1 was decreased in 5-FU-treated colon cancer cells compared to untreated cells; APAF-1 as a target gene of miR-23a was identified and miR-23a antisense-induced increase in the activation of caspase-9 was observed |
21 | hsa-miR-23b-3p | APAF1 | -0.58 | 0.19048 | 0.35 | 0.33131 | miRNATAP | -0.16 | 0.00048 | NA | |
22 | hsa-miR-27a-3p | APAF1 | 1.76 | 0.00022 | 0.35 | 0.33131 | miRNATAP | -0.18 | 3.0E-5 | NA | |
23 | hsa-miR-27b-3p | APAF1 | -0.09 | 0.85847 | 0.35 | 0.33131 | miRNATAP | -0.16 | 6.0E-5 | NA | |
24 | hsa-miR-33a-3p | APAF1 | 2.06 | 0.00156 | 0.35 | 0.33131 | mirMAP | -0.06 | 0.0393 | NA | |
25 | hsa-miR-374b-5p | APAF1 | -0.11 | 0.76489 | 0.35 | 0.33131 | mirMAP | -0.13 | 0.01531 | NA | |
26 | hsa-miR-590-3p | APAF1 | 2.35 | 0 | 0.35 | 0.33131 | PITA; miRanda; mirMAP; miRNATAP | -0.12 | 0.0034 | NA | |
27 | hsa-miR-590-5p | APAF1 | 1.51 | 0.00239 | 0.35 | 0.33131 | miRanda | -0.1 | 0.01383 | NA | |
28 | hsa-miR-664a-3p | APAF1 | 0.25 | 0.56171 | 0.35 | 0.33131 | mirMAP | -0.11 | 0.01914 | NA | |
29 | hsa-miR-708-3p | APAF1 | 0.78 | 0.29065 | 0.35 | 0.33131 | mirMAP | -0.12 | 2.0E-5 | NA | |
30 | hsa-miR-18a-5p | ATM | 3.91 | 0 | -0.66 | 0.11688 | miRNAWalker2 validate; miRTarBase; MirTarget | -0.1 | 0.00848 | 25963391; 23437304; 23857602; 23229340 | However the upregulation of miR-18a suppressed the level of ataxia-telangiectasia mutated and attenuated DNA double-strand break repair after irradiation which re-sensitized the cervical cancer cells to radiotherapy by promoting apoptosis;MicroRNA 18a attenuates DNA damage repair through suppressing the expression of ataxia telangiectasia mutated in colorectal cancer; Through in silico search the 3'UTR of Ataxia telangiectasia mutated ATM contains a conserved miR-18a binding site; Expression of ATM was down-regulated in CRC tumors p<0.0001 and inversely correlated with miR-18a expression r = -0.4562 p<0.01; This was further confirmed by the down-regulation of ATM protein by miR-18a; As ATM is a key enzyme in DNA damage repair we evaluated the effect of miR-18a on DNA double-strand breaks; miR-18a attenuates cellular repair of DNA double-strand breaks by directly suppressing ATM a key enzyme in DNA damage repair;Furthermore we used antisense oligonucleotides against micro RNAs miRNA or miRNA overexpression plasmids to study the role of miR-18a and -106a on ATM expression; Furthermore we identified that ERα activates miR-18a and -106a to downregulate ATM expression; We reveal a novel mechanism involving ERα and miR-18a and -106a regulation of ATM in breast cancer;MicroRNA 18a upregulates autophagy and ataxia telangiectasia mutated gene expression in HCT116 colon cancer cells; Previous studies showed that certain microRNAs including miR-18a potentially regulate ATM in cancer cells; However the mechanisms behind the modulation of ATM by miR-18a remain to be elucidated in colon cancer cells; In the present study we explored the impact of miR-18a on the autophagy process and ATM expression in HCT116 colon cancer cells; Western blotting and luciferase assays were implemented to explore the impact of miR-18a on ATM gene expression in HCT116 cells; Moreover miR-18a overexpression led to the upregulation of ATM expression and suppression of mTORC1 activity; Results of the present study pertaining to the role of miR-18a in regulating autophagy and ATM gene expression in colon cancer cells revealed a novel function for miR-18a in a critical cellular event and on a crucial gene with significant impacts in cancer development progression treatment and in other diseases |
31 | hsa-miR-19b-3p | ATM | 1.68 | 0.00086 | -0.66 | 0.11688 | miRNAWalker2 validate | -0.1 | 0.04453 | NA | |
32 | hsa-miR-203a-3p | ATM | 6.35 | 0 | -0.66 | 0.11688 | MirTarget | -0.11 | 0 | 24145123; 27542403 | miR 203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase; In silico analysis identified ataxia telangiectasia mutated ATM a primary mediator of the DNA damage response as a potential target of miR-203; Using TCGA database we identified a significant reverse correlation of miR-203 and ATM expression in CRC tissues; We validated ATM as a bona fide target of miR-203 in CRC cells; Mutation of the putative miR-203 binding site in the 3' untranslated region 3'UTR of the ATM mRNA abolished the inhibitory effect of miR-203 on ATM;MiR 203 inhibits tumor invasion and metastasis in gastric cancer by ATM; Our results showed that miR-203 was significantly downregulated in gastric cancer tissues and cells while ataxia telangiectasia mutated kinase ATM was upregulated in gastric cancer tissues and cells and was directly regulated by miR-203; ATM knockdown phenocopied the effect of miR-203 overexpression |
33 | hsa-miR-27a-5p | ATM | 1.45 | 0.03942 | -0.66 | 0.11688 | MirTarget | -0.12 | 0.00046 | NA | |
34 | hsa-miR-30e-3p | ATM | -0.04 | 0.93258 | -0.66 | 0.11688 | mirMAP | -0.16 | 0.0051 | NA | |
35 | hsa-miR-335-3p | ATM | 1.2 | 0.09389 | -0.66 | 0.11688 | mirMAP | -0.07 | 0.02605 | NA | |
36 | hsa-miR-339-5p | ATM | 1.23 | 0.03075 | -0.66 | 0.11688 | miRanda | -0.16 | 0.00017 | NA | |
37 | hsa-miR-34c-5p | ATM | 2.65 | 0.01574 | -0.66 | 0.11688 | miRanda | -0.05 | 0.01287 | NA | |
38 | hsa-miR-590-3p | ATM | 2.35 | 0 | -0.66 | 0.11688 | miRanda; mirMAP | -0.12 | 0.01272 | NA | |
39 | hsa-miR-590-5p | ATM | 1.51 | 0.00239 | -0.66 | 0.11688 | mirMAP | -0.13 | 0.00485 | NA | |
40 | hsa-miR-92a-3p | ATM | 1.88 | 1.0E-5 | -0.66 | 0.11688 | miRNAWalker2 validate | -0.14 | 0.01126 | NA | |
41 | hsa-miR-944 | ATM | 7.21 | 0.00082 | -0.66 | 0.11688 | mirMAP | -0.08 | 0 | NA | |
42 | hsa-miR-127-3p | BAD | -1.38 | 0.0732 | -0.43 | 0.27401 | miRanda; miRNATAP | -0.06 | 0.04432 | NA | |
43 | hsa-miR-15b-3p | BCL2 | 3.58 | 0 | -3.06 | 1.0E-5 | mirMAP | -0.16 | 0.0243 | 25594541; 26915294; 26884837; 18449891 | MicroRNAs miRNAs encoded by the miR-15 cluster are known to induce G1 arrest and apoptosis by targeting G1 checkpoints and the anti-apoptotic B cell lymphoma 2 BCL-2 gene;As a result transcript levels of the tumor-suppressive miR-15 and let-7 families increased which targeted and decreased the expression of the crucial prosurvival genes BCL-2 and BCL-XL respectively;MiR 15b mediates liver cancer cells proliferation through targeting BCL 2; MiR-15b overexpression downregulated BCL2 mRNA and protein expression obviously P < 0.05; On the contrary miR-15b inhibitor transfection markedly reduced miR-15b expression in liver cancer cells P < 0.05 promoted tumor cell proliferation and increased BCL2 mRNA and protein expression; MiR-15b can inhibit HepG2 cell proliferation and down-regulate BCL2 mRNA and protein expression;miR 15b and miR 16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells; The downregulation of miR-15b and miR-16 in SGC7901/VCR cells was concurrent with the upregulation of Bcl-2 protein; Taken together our findings suggest that miR-15b and miR-16 could play a role in the development of MDR in gastric cancer cells at least in part by modulation of apoptosis via targeting BCL2 |
44 | hsa-miR-15b-5p | BCL2 | 3.32 | 0 | -3.06 | 1.0E-5 | miRNAWalker2 validate; miRTarBase | -0.18 | 0.02793 | 25594541; 26915294; 26884837; 18449891 | MicroRNAs miRNAs encoded by the miR-15 cluster are known to induce G1 arrest and apoptosis by targeting G1 checkpoints and the anti-apoptotic B cell lymphoma 2 BCL-2 gene;As a result transcript levels of the tumor-suppressive miR-15 and let-7 families increased which targeted and decreased the expression of the crucial prosurvival genes BCL-2 and BCL-XL respectively;MiR 15b mediates liver cancer cells proliferation through targeting BCL 2; MiR-15b overexpression downregulated BCL2 mRNA and protein expression obviously P < 0.05; On the contrary miR-15b inhibitor transfection markedly reduced miR-15b expression in liver cancer cells P < 0.05 promoted tumor cell proliferation and increased BCL2 mRNA and protein expression; MiR-15b can inhibit HepG2 cell proliferation and down-regulate BCL2 mRNA and protein expression;miR 15b and miR 16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells; The downregulation of miR-15b and miR-16 in SGC7901/VCR cells was concurrent with the upregulation of Bcl-2 protein; Taken together our findings suggest that miR-15b and miR-16 could play a role in the development of MDR in gastric cancer cells at least in part by modulation of apoptosis via targeting BCL2 |
45 | hsa-miR-16-2-3p | BCL2 | 3.8 | 0 | -3.06 | 1.0E-5 | mirMAP | -0.2 | 0.00813 | NA | |
46 | hsa-miR-16-5p | BCL2 | 2.94 | 0 | -3.06 | 1.0E-5 | miRNAWalker2 validate; miRTarBase | -0.27 | 0.00125 | 21336967; 24447552; 18449891; 25435430; 24598659; 18931683; 22966344; 25623762 | P glycoprotein enhances radiation induced apoptotic cell death through the regulation of miR 16 and Bcl 2 expressions in hepatocellular carcinoma cells; RHepG2 cells the multidrug resistant subline of human hepatocellular carcinoma HepG2 cells expressed higher levels of Pgp as well as miR-16 and lower level of Bcl-2 than the parental cells; On the other hand ectopic mdr1 expression enhanced radiation-induced apoptosis in HepG2 cells SK-HEP-1 cells MiHa cells and furthermore induced miR-16 and suppressed its target gene Bcl-2 in HepG2 cells; Moreover the enhancement effects of Pgp and miR-16 on radiation-induced apoptosis were counteracted by overexpression of Bcl-2;To study the expression of miR-16 and bcl-2 in T lymphoblastic lymphoma/leukemia T-LBL/ALL and its relationship to prognosis; The relationship of miR-16 and bcl-2 was significantP = 0.042χ2 = 4.147; The relationship of miR-16 and bcl-2 might suggested that gene regulation may be influenced by them;miR 15b and miR 16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells; The downregulation of miR-15b and miR-16 in SGC7901/VCR cells was concurrent with the upregulation of Bcl-2 protein; Taken together our findings suggest that miR-15b and miR-16 could play a role in the development of MDR in gastric cancer cells at least in part by modulation of apoptosis via targeting BCL2;We demonstrated that anti-apoptotic protein Bcl-2 was directly targeted miR-16 in paclitaxel resistant lung cancer cells; Combined overexpression of miR-16 and miR-17 greatly reduced Beclin-1 and Bcl-2 expressions respectively; miR-17 overexpression reduced cytoprotective autophagy by targeting Beclin-1 whereas overexpression of miR-16 potentiated paclitaxel induced apoptotic cell death by inhibiting anti-apoptotic protein Bcl-2;The miR-16 expression correlated with BCL-2 protein r = 0.51 P < 0.05;MicroRNAs miRNAs are noncoding small RNAs that repress protein translation by targeting specific messenger RNAs miR-15a and miR-16-1 act as putative tumor suppressors by targeting the oncogene BCL2;The overall objective of our investigation was to assess whether miRNA-16 miR-16 is involved in the regulation of critical genes such as BCL2 that control the sensitivity of pancreatic cancer cells to apoptosis; This study showed that the ectopic overexpression of miR-16 may be therapeutically beneficial as is evidenced by impaired cell survival with concomitant attenuation of anti-apoptotic protein Bcl-2; Moreover the luciferase reporter assay suggested that miR-16 post-transcriptionally regulates Bcl-2 expression in pancreatic cancer cells through the target sites of the 3' untranslated region of this gene;miR 15a and miR 16 modulate drug resistance by targeting bcl 2 in human colon cancer cells; To investigate the reversal effect of targeted modulation of bcl-2 expression by miR-15a and miR-16 on drug resistance of human colon cancer cells |
47 | hsa-miR-192-5p | BCL2 | 1.78 | 0.11349 | -3.06 | 1.0E-5 | miRNAWalker2 validate | -0.13 | 0.00025 | 26550150 | MicroRNA 192 regulates chemo resistance of lung adenocarcinoma for gemcitabine and cisplatin combined therapy by targeting Bcl 2; In this paper we try to test whether miR-192 regulates chemo-resistance in human carcinoma A549 mice model by targeting Bcl-2; MTT assay real-time RT-PCR western blotting assay were used to investigate miR-192 expression levels cell viability ratio and Bcl-2 protein expression levels; Bcl-2 mRNA and protein expression levels up-regulated in miR-192 inhibitor treated tumor; Bcl-2 is a key regulator for miR-192 related chemotherapy resistance; In this study we demonstrate that miR-192 regulates chemoresistance for gemcitabine and cisplatin combined chemotherapy in human adenocarcinoma lung cancer A549 cells and Bcl-2 is the target of miR-192 |
48 | hsa-miR-200a-5p | BCL2 | 6.52 | 0 | -3.06 | 1.0E-5 | mirMAP | -0.2 | 0.00037 | NA | |
49 | hsa-miR-200b-3p | BCL2 | 5.56 | 0 | -3.06 | 1.0E-5 | miRNAWalker2 validate; miRTarBase; TargetScan; mirMAP | -0.11 | 0.03933 | NA | |
50 | hsa-miR-200b-5p | BCL2 | 6.82 | 0 | -3.06 | 1.0E-5 | mirMAP | -0.2 | 0.00019 | NA | |
51 | hsa-miR-200c-3p | BCL2 | 6.47 | 0 | -3.06 | 1.0E-5 | miRNAWalker2 validate; miRTarBase; mirMAP | -0.2 | 0.00073 | NA | |
52 | hsa-miR-20a-3p | BCL2 | 1.99 | 0.00062 | -3.06 | 1.0E-5 | mirMAP | -0.16 | 0.0222 | NA | |
53 | hsa-miR-21-5p | BCL2 | 2.65 | 0 | -3.06 | 1.0E-5 | miRNAWalker2 validate; miRTarBase | -0.48 | 4.0E-5 | 21468550; 25994220; 25381586; 26555418; 23359184; 22964582; 21376256 | BCL-2 up-regulation could be achieved by miR-21 overexpression which prevented T24 cells from apoptosis induced by doxorubicin; Furthermore the miR-21 induced BCL-2 up-regulation could be cancelled by the PI3K inhibitor LY294002;Meanwhile miR-21 loss reduced STAT3 and Bcl-2 activation causing an increase in the apoptosis of tumour cells in CAC mice;Changes in the sensitivity of osteosarcoma cells to CDDP were examined after transfection with miR-21 mimics or anti-miR-21 or bcl-2 siRNA in combination with CDDP;The expression of Bax Bcl-2 and miR-21 in parental and paclitaxel-resistant cells was detected by RT-PCR and Western blotting;Resveratrol induces apoptosis of pancreatic cancers cells by inhibiting miR 21 regulation of BCL 2 expression; We also used Western blot to measure BCL-2 protein levels after down-regulation of miR-21 expression; Besides down-regulation of miR-21 expression can inhibit BCL-2 expression in PANC-1 CFPAC-1 and MIA Paca-2 cells; Over-expression of miR-21 expression can reverse down-regulation of BCL-2 expression and apoptosis induced by resveratrol; In this study we demonstrated that the effect of resveratrol on apoptosis is due to inhibiting miR-21 regulation of BCL-2 expression;Tumors harvested from these lungs have elevated levels of oncogenic miRNAs miR-21 and miR-155; are deficient for p53-regulated miRNAs; and have heightened expression of miR-34 target genes such as Met and Bcl-2;Bcl 2 upregulation induced by miR 21 via a direct interaction is associated with apoptosis and chemoresistance in MIA PaCa 2 pancreatic cancer cells; However the roles and mechanisms of miRNA miR-21 in regulation of Bcl-2 in pancreatic cancer remain to be elucidated; Then luciferase activity was observed after miR-21 mimics and pRL-TK plasmids containing wild-type and mutant 3'UTRs of Bcl-2 mRNA were co-transfected; Cells transfected with miR-21 inhibitor revealed an opposite trend. There was a significant increase in luciferase activity in the cells transfected with the wild-type pRL-TK plasmid in contrast to those transfected with the mutant one indicating that miR-21 promotes Bcl-2 expression by binding directly to the 3'UTR of Bcl-2 mRNA; Upregulation of Bcl-2 directly induced by miR-21 is associated with apoptosis chemoresistance and proliferation of MIA PaCa-2 pancreatic cancer cells |
54 | hsa-miR-215-5p | BCL2 | 3.67 | 0.00295 | -3.06 | 1.0E-5 | miRNAWalker2 validate | -0.14 | 1.0E-5 | NA | |
55 | hsa-miR-24-2-5p | BCL2 | 2.07 | 6.0E-5 | -3.06 | 1.0E-5 | miRNAWalker2 validate; miRTarBase | -0.36 | 0 | NA | |
56 | hsa-miR-3065-5p | BCL2 | 2.14 | 0.06094 | -3.06 | 1.0E-5 | mirMAP | -0.17 | 0.00011 | NA | |
57 | hsa-miR-32-3p | BCL2 | 2.2 | 0.03928 | -3.06 | 1.0E-5 | mirMAP | -0.16 | 0.01564 | NA | |
58 | hsa-miR-338-5p | BCL2 | -0.11 | 0.89468 | -3.06 | 1.0E-5 | PITA | -0.15 | 0.00173 | NA | |
59 | hsa-miR-33b-5p | BCL2 | 4.78 | 0 | -3.06 | 1.0E-5 | miRTarBase; mirMAP | -0.12 | 0.00899 | NA | |
60 | hsa-miR-365a-3p | BCL2 | 0.26 | 0.65432 | -3.06 | 1.0E-5 | miRNAWalker2 validate; miRTarBase | -0.39 | 0 | NA | |
61 | hsa-miR-375 | BCL2 | 3.38 | 0.04499 | -3.06 | 1.0E-5 | miRNAWalker2 validate | -0.06 | 0.01035 | 26381132; 26697569; 25613180 | The levels of miR-375 Bax and Bcl-2 protein expression in treated cells were determined by Western blot and RT-PCR; Moreover compared to control group the expression of Bcl-2 and miR-375 decreases with formononetin in the U2OS cells while Bax increases;Exosome Carried microRNA 375 Inhibits Cell Progression and Dissemination via Bcl 2 Blocking in Colon Cancer; RT-PCR for Bcl-2 expression showed that Bcl-2 is down-regulated for miR-375 inhibitor and up-regulated for the miR-375 mimic a result confirmed by Western blotting; The present study brings to the forefront new data that suggest miR-375 as a new player in controlling the pathways responsible for inhibiting the natural history of CRC tumor cells via the Bcl-2 pathway;mRNA levels of ERα Bcl-2 and miR-375 were quantified using real-time polymerase chain reaction; After treatment with biochanin A ERα miR-375 and Bcl-2 expression was significantly upregulated |
62 | hsa-miR-429 | BCL2 | 6.4 | 0 | -3.06 | 1.0E-5 | miRNAWalker2 validate; miRTarBase; PITA; mirMAP | -0.16 | 0.00181 | 23999873; 26513239; 26511969 | MiR 429 up regulation induces apoptosis and suppresses invasion by targeting Bcl 2 and SP 1 in esophageal carcinoma; Subsequent Western blotting and luciferase reporter assays showed that miR-429 can bind to putative binding sites within the Bcl-2 and SP1 mRNA 3' untranslated regions UTRs to reduce their expression; Up-regulation of miR-429 inhibits invasion and promotes apoptosis in EC cells by targeting Bcl-2 and SP1; Our findings suggest that Bcl-2 and SP1 may serve as major targets of miR-429;MiR 429 Induces Gastric Carcinoma Cell Apoptosis Through Bcl 2; Here we studied the levels of miR-429 and anti-apoptotic protein Bcl-2 in GC specimens; We performed bioinformatics analyses and used luciferase-reporter assay to analyze the relationship between miR-429 and Bcl-2 in GC cells; MiR-429 levels were significantly decreased and Bcl-2 levels were significantly increased in GC specimens compared to the paired adjacent non-tumor gastric tissue; Moreover the levels of miR-429 and Bcl-2 inversely correlated in GC specimens; Bioinformatics analyses showed that miR-429 targeted the 3'-UTR of Bcl-2 mRNA to inhibit its translation which was confirmed by luciferase-reporter assay;MiR 429 induces apoptosis of glioblastoma cell through Bcl 2; Here we analyzed the levels of miR-429 and anti-apoptotic protein Bcl-2 in GBM specimens; We combined bioinformatics analyses and luciferase reporter assay to determine the relationship between miR-429 and Bcl-2 in GBM cells; We found that miR-429 levels were significantly decreased and Bcl-2 levels were significantly increased in GBM specimens compared to the paired adjacent non-tumor brain tissue; Moreover the levels of miR-429 and Bcl-2 inversely correlated; MiR-429 targeted the 3'-UTR of Bcl-2 mRNA to inhibit its translation |
63 | hsa-miR-451a | BCL2 | 0.95 | 0.43831 | -3.06 | 1.0E-5 | miRNAWalker2 validate; miRTarBase | -0.07 | 0.04266 | 26516138; 23053883 | Western blot was used for the detection of the protein expression of Bcl-2 and Caspase 3 after the transfection of miR-451 mimics /inhibitors; Bioinformatics analysis demonstrated that Bcl-2 protein is a potential target gene for miR-451; Increased miR-451 expression may negatively regulate Bcl-2 mRNA and protein expression followed by affecting the protein expression of caspase 3 and accelerate the apoptosis in breast cancer indicating that miR-451 might influence the drug resistances of the Paclitaxel-resistant breast cancer cell line;The expression of miR-451 was analyzed by RT-PCR and the expressions of Bcl-2 AKT and phosphorylated AKT were analyzed by Western blotting; In comparison to the controls a significant increase in the expression of miR-451 was associated with significantly decreased expressions of Bcl-2 AKT and p-AKT and a significant increase in the apoptosis rate |
64 | hsa-miR-582-5p | BCL2 | 0.69 | 0.44776 | -3.06 | 1.0E-5 | PITA | -0.13 | 0.00231 | NA | |
65 | hsa-miR-590-5p | BCL2 | 1.51 | 0.00239 | -3.06 | 1.0E-5 | miRanda | -0.17 | 0.03245 | NA | |
66 | hsa-miR-629-5p | BCL2 | 1.57 | 0.01157 | -3.06 | 1.0E-5 | mirMAP | -0.25 | 7.0E-5 | NA | |
67 | hsa-miR-7-5p | BCL2 | 3.6 | 0.00068 | -3.06 | 1.0E-5 | miRNAWalker2 validate; miRTarBase; mirMAP | -0.12 | 0.00725 | 26464649; 25862909; 21750649 | Western blotting was used to evaluate the effect of miR-7 on Bcl2 in A549 and H460 cells; Moreover subsequent experiments showed that BCL-2 was downregulated by miR-7 at both transcriptional and translational levels; This study further extends the biological role of miR-7 in NSCLC A549 and H460 cells and identifies BCL-2 as a novel target possibly involved in miR-7-mediated growth suppression and apoptosis induction of NSCLC cells;miR-7 overexpression correlated with diminished BCL2 expression but there was no relationship between miR-7 and EGFR expression neither in tumour samples nor in the cell lines; Of the two postulated miR-7 target genes we examined BCL2 but not EGFR seems to be a possible miR-7 target in OC;Bioinformatics predictions revealed a potential binding site of miR-7 on 3'UTR of BCL-2 and it was further confirmed by luciferase assay; Moreover subsequent experiments showed that BCL-2 was downregulated by miR-7 at both transcriptional and translational levels; These results suggest that miR-7 regulates the expression of BCL-2 through direct 3'UTR interactions |
68 | hsa-let-7a-5p | BCL2L1 | 0.15 | 0.64531 | 0.39 | 0.37256 | TargetScan; miRNATAP | -0.2 | 0.01274 | 26915294; 20347499 | As a result transcript levels of the tumor-suppressive miR-15 and let-7 families increased which targeted and decreased the expression of the crucial prosurvival genes BCL-2 and BCL-XL respectively;The let 7 family of microRNAs inhibits Bcl xL expression and potentiates sorafenib induced apoptosis in human hepatocellular carcinoma; The effect of let-7 on Bcl-xL expression was examined by Western blot and a reporter assay; Microarray analysis followed by in silico target prediction identified let-7 microRNAs as being downregulated in Huh7 hepatoma cells in comparison with primary human hepatocytes as well as possessing a putative target site in the bcl-xl mRNA |
69 | hsa-miR-23b-3p | BCL2L1 | -0.58 | 0.19048 | 0.39 | 0.37256 | miRNAWalker2 validate | -0.11 | 0.04171 | NA | |
70 | hsa-miR-342-3p | BCL2L1 | 1.31 | 0.02072 | 0.39 | 0.37256 | PITA; miRanda; miRNATAP | -0.13 | 0.00344 | NA | |
71 | hsa-miR-342-5p | BCL2L1 | 1.39 | 0.01536 | 0.39 | 0.37256 | miRNATAP | -0.1 | 0.01901 | NA | |
72 | hsa-miR-195-3p | BIRC3 | -2.39 | 0.00019 | 0.15 | 0.88569 | mirMAP | -0.22 | 0.01884 | NA | |
73 | hsa-miR-20b-3p | BIRC3 | 3.33 | 0.06324 | 0.15 | 0.88569 | MirTarget | -0.13 | 0.02697 | NA | |
74 | hsa-miR-24-1-5p | BIRC3 | -0.64 | 0.23613 | 0.15 | 0.88569 | MirTarget | -0.36 | 0.00121 | NA | |
75 | hsa-miR-369-3p | BIRC3 | 0.37 | 0.63876 | 0.15 | 0.88569 | MirTarget; miRNATAP | -0.15 | 0.04648 | NA | |
76 | hsa-miR-664a-3p | BIRC3 | 0.25 | 0.56171 | 0.15 | 0.88569 | mirMAP | -0.28 | 0.04632 | NA | |
77 | hsa-miR-491-5p | CAPN1 | 0.57 | 0.31331 | 1.31 | 0.00019 | miRanda | -0.15 | 5.0E-5 | NA | |
78 | hsa-miR-107 | CAPN2 | 1.49 | 0.00013 | 0.65 | 0.13872 | miRanda | -0.13 | 0.04866 | NA | |
79 | hsa-miR-1468-5p | CAPN2 | -1.63 | 0.00779 | 0.65 | 0.13872 | MirTarget | -0.2 | 0 | NA | |
80 | hsa-miR-20a-3p | CAPN2 | 1.99 | 0.00062 | 0.65 | 0.13872 | MirTarget | -0.14 | 0.00093 | NA | |
81 | hsa-miR-30a-5p | CAPN2 | -0.77 | 0.32049 | 0.65 | 0.13872 | miRNAWalker2 validate | -0.08 | 0.01733 | NA | |
82 | hsa-miR-421 | CAPN2 | 1.98 | 0.00092 | 0.65 | 0.13872 | miRanda | -0.11 | 0.00888 | NA | |
83 | hsa-miR-125b-5p | CASP10 | -2.01 | 0.00516 | 0.7 | 0.33671 | mirMAP | -0.15 | 0.00696 | NA | |
84 | hsa-miR-129-5p | CASP10 | -2.67 | 0.00696 | 0.7 | 0.33671 | mirMAP | -0.1 | 0.02215 | NA | |
85 | hsa-miR-145-3p | CASP10 | -2.96 | 0 | 0.7 | 0.33671 | mirMAP | -0.15 | 0.02154 | NA | |
86 | hsa-miR-145-5p | CASP10 | -3.56 | 0 | 0.7 | 0.33671 | mirMAP | -0.14 | 0.01213 | NA | |
87 | hsa-miR-186-5p | CASP10 | 0.45 | 0.18545 | 0.7 | 0.33671 | MirTarget; mirMAP | -0.26 | 0.04094 | NA | |
88 | hsa-miR-19b-3p | CASP10 | 1.68 | 0.00086 | 0.7 | 0.33671 | MirTarget; mirMAP | -0.2 | 0.01385 | NA | |
89 | hsa-miR-33a-3p | CASP10 | 2.06 | 0.00156 | 0.7 | 0.33671 | mirMAP | -0.16 | 0.01181 | NA | |
90 | hsa-miR-361-5p | CASP10 | 0.01 | 0.9852 | 0.7 | 0.33671 | miRanda | -0.46 | 0.00011 | NA | |
91 | hsa-miR-429 | CASP10 | 6.4 | 0 | 0.7 | 0.33671 | mirMAP; miRNATAP | -0.13 | 0.01667 | NA | |
92 | hsa-miR-501-5p | CASP10 | 1.04 | 0.07772 | 0.7 | 0.33671 | mirMAP | -0.16 | 0.01989 | NA | |
93 | hsa-miR-532-5p | CASP10 | -0.3 | 0.50393 | 0.7 | 0.33671 | mirMAP | -0.47 | 0 | NA | |
94 | hsa-miR-589-3p | CASP10 | 1.33 | 0.05263 | 0.7 | 0.33671 | mirMAP | -0.23 | 0.00013 | NA | |
95 | hsa-miR-592 | CASP10 | 2.8 | 0.02935 | 0.7 | 0.33671 | miRNATAP | -0.1 | 0.0073 | NA | |
96 | hsa-miR-744-3p | CASP10 | 1.08 | 0.13124 | 0.7 | 0.33671 | mirMAP | -0.39 | 0 | NA | |
97 | hsa-miR-129-5p | CASP3 | -2.67 | 0.00696 | 0.93 | 0.00553 | mirMAP | -0.05 | 0.00602 | 23744359 | The intrinsic apoptotic pathway triggered by miR-129 was activated by cleavage of caspase-9 and caspase-3 |
98 | hsa-miR-193b-5p | CASP3 | 0.45 | 0.56588 | 0.93 | 0.00553 | MirTarget | -0.09 | 0.00034 | NA | |
99 | hsa-miR-23a-3p | CASP7 | 0.93 | 0.01273 | 0.55 | 0.21498 | MirTarget | -0.16 | 0.02185 | NA | |
100 | hsa-miR-335-5p | CASP7 | 0.17 | 0.8039 | 0.55 | 0.21498 | MirTarget | -0.1 | 0.01049 | NA | |
101 | hsa-miR-361-5p | CASP7 | 0.01 | 0.9852 | 0.55 | 0.21498 | PITA; miRanda | -0.2 | 0.00762 | NA | |
102 | hsa-miR-664a-3p | CASP7 | 0.25 | 0.56171 | 0.55 | 0.21498 | MirTarget | -0.14 | 0.02009 | NA | |
103 | hsa-miR-217 | CASP8 | -0.38 | 0.71741 | 1.38 | 0.00022 | miRanda | -0.06 | 0.00539 | NA | |
104 | hsa-miR-455-5p | CASP8 | -0.32 | 0.6163 | 1.38 | 0.00022 | miRanda | -0.09 | 0.00884 | NA | |
105 | hsa-miR-222-5p | CASP9 | 2.52 | 0.00142 | -0.46 | 0.19687 | mirMAP | -0.08 | 0.0009 | NA | |
106 | hsa-miR-125a-5p | CFLAR | -1.32 | 0.00714 | 0.11 | 0.78588 | miRanda | -0.13 | 0.0064 | NA | |
107 | hsa-miR-130b-3p | CFLAR | 3.92 | 0 | 0.11 | 0.78588 | mirMAP | -0.14 | 0.00031 | NA | |
108 | hsa-miR-15b-5p | CFLAR | 3.32 | 0 | 0.11 | 0.78588 | mirMAP | -0.1 | 0.03067 | NA | |
109 | hsa-miR-301a-3p | CFLAR | 1.99 | 0.00081 | 0.11 | 0.78588 | mirMAP | -0.14 | 0.00017 | NA | |
110 | hsa-miR-30b-3p | CFLAR | 0.17 | 0.76608 | 0.11 | 0.78588 | mirMAP | -0.16 | 7.0E-5 | NA | |
111 | hsa-miR-497-5p | CFLAR | -1.44 | 0.02251 | 0.11 | 0.78588 | mirMAP | -0.08 | 0.03415 | NA | |
112 | hsa-miR-708-5p | CFLAR | 1.7 | 0.03195 | 0.11 | 0.78588 | mirMAP | -0.06 | 0.02422 | NA | |
113 | hsa-miR-9-5p | CFLAR | 1.8 | 0.14527 | 0.11 | 0.78588 | mirMAP | -0.07 | 0.00032 | NA | |
114 | hsa-miR-582-5p | CHP2 | 0.69 | 0.44776 | 1.48 | 0.50956 | miRNATAP | -0.42 | 0.00313 | NA | |
115 | hsa-miR-195-5p | CHUK | -1.59 | 0.01691 | 0.41 | 0.12085 | miRNAWalker2 validate; MirTarget | -0.05 | 0.02493 | NA | |
116 | hsa-miR-497-5p | CHUK | -1.44 | 0.02251 | 0.41 | 0.12085 | MirTarget | -0.07 | 0.00184 | NA | |
117 | hsa-miR-15b-3p | CSF2RB | 3.58 | 0 | -0.53 | 0.5247 | mirMAP | -0.24 | 0.00379 | NA | |
118 | hsa-miR-19b-3p | CSF2RB | 1.68 | 0.00086 | -0.53 | 0.5247 | MirTarget | -0.25 | 0.00793 | NA | |
119 | hsa-miR-30b-3p | CSF2RB | 0.17 | 0.76608 | -0.53 | 0.5247 | MirTarget | -0.28 | 0.00087 | NA | |
120 | hsa-miR-532-5p | CSF2RB | -0.3 | 0.50393 | -0.53 | 0.5247 | MirTarget | -0.22 | 0.0443 | NA | |
121 | hsa-miR-30a-3p | DFFA | -1.22 | 0.16757 | 0.34 | 0.23076 | mirMAP | -0.06 | 0.00088 | NA | |
122 | hsa-miR-3913-5p | DFFA | 0.15 | 0.73484 | 0.34 | 0.23076 | mirMAP | -0.08 | 0.03385 | NA | |
123 | hsa-miR-628-5p | DFFA | 1.05 | 0.02524 | 0.34 | 0.23076 | mirMAP | -0.07 | 0.03581 | NA | |
124 | hsa-miR-365a-3p | DFFB | 0.26 | 0.65432 | -0.13 | 0.73678 | MirTarget | -0.1 | 0.00471 | NA | |
125 | hsa-miR-130b-3p | ENDOD1 | 3.92 | 0 | -1.15 | 0.01857 | MirTarget | -0.12 | 0.00768 | NA | |
126 | hsa-miR-16-1-3p | ENDOD1 | 2.83 | 0 | -1.15 | 0.01857 | mirMAP | -0.14 | 0.01455 | NA | |
127 | hsa-miR-181a-5p | ENDOD1 | 1.26 | 0.00749 | -1.15 | 0.01857 | MirTarget | -0.19 | 0.00156 | NA | |
128 | hsa-miR-181b-5p | ENDOD1 | 1.11 | 0.02734 | -1.15 | 0.01857 | MirTarget | -0.12 | 0.02423 | NA | |
129 | hsa-miR-181c-5p | ENDOD1 | -0.3 | 0.53753 | -1.15 | 0.01857 | MirTarget | -0.19 | 0.00075 | NA | |
130 | hsa-miR-192-5p | ENDOD1 | 1.78 | 0.11349 | -1.15 | 0.01857 | miRNAWalker2 validate | -0.09 | 0.00044 | NA | |
131 | hsa-miR-19a-3p | ENDOD1 | 2.17 | 0.00122 | -1.15 | 0.01857 | mirMAP | -0.12 | 0.00261 | NA | |
132 | hsa-miR-19b-3p | ENDOD1 | 1.68 | 0.00086 | -1.15 | 0.01857 | mirMAP | -0.16 | 0.0036 | NA | |
133 | hsa-miR-200b-3p | ENDOD1 | 5.56 | 0 | -1.15 | 0.01857 | TargetScan | -0.13 | 0.00092 | NA | |
134 | hsa-miR-20a-3p | ENDOD1 | 1.99 | 0.00062 | -1.15 | 0.01857 | MirTarget | -0.1 | 0.0432 | NA | |
135 | hsa-miR-26b-3p | ENDOD1 | 0.99 | 0.03514 | -1.15 | 0.01857 | mirMAP | -0.15 | 0.00987 | NA | |
136 | hsa-miR-301a-3p | ENDOD1 | 1.99 | 0.00081 | -1.15 | 0.01857 | MirTarget | -0.13 | 0.00488 | NA | |
137 | hsa-miR-3607-3p | ENDOD1 | 1.38 | 0.02401 | -1.15 | 0.01857 | MirTarget; miRNATAP | -0.11 | 0.01385 | NA | |
138 | hsa-miR-3613-5p | ENDOD1 | 4.05 | 0 | -1.15 | 0.01857 | MirTarget | -0.2 | 4.0E-5 | NA | |
139 | hsa-miR-362-3p | ENDOD1 | 0.68 | 0.22615 | -1.15 | 0.01857 | miRanda | -0.18 | 0.00023 | NA | |
140 | hsa-miR-429 | ENDOD1 | 6.4 | 0 | -1.15 | 0.01857 | miRanda; miRNATAP | -0.1 | 0.00627 | NA | |
141 | hsa-miR-454-3p | ENDOD1 | 1.4 | 0.00366 | -1.15 | 0.01857 | MirTarget | -0.23 | 4.0E-5 | NA | |
142 | hsa-miR-589-3p | ENDOD1 | 1.33 | 0.05263 | -1.15 | 0.01857 | mirMAP | -0.1 | 0.0115 | NA | |
143 | hsa-miR-589-5p | ENDOD1 | 1.56 | 0.00033 | -1.15 | 0.01857 | MirTarget | -0.18 | 0.0056 | NA | |
144 | hsa-miR-590-3p | ENDOD1 | 2.35 | 0 | -1.15 | 0.01857 | miRanda | -0.22 | 7.0E-5 | NA | |
145 | hsa-miR-149-5p | EXOG | 1.19 | 0.19744 | -0.06 | 0.85895 | MirTarget | -0.06 | 0.00548 | NA | |
146 | hsa-miR-24-3p | EXOG | 1.56 | 0.00052 | -0.06 | 0.85895 | MirTarget | -0.14 | 0.00075 | NA | |
147 | hsa-miR-106a-5p | FAS | 3.99 | 0 | -0.34 | 0.58934 | miRNAWalker2 validate; miRTarBase | -0.14 | 0.00128 | 22431000; 27142596 | miR 106a is frequently upregulated in gastric cancer and inhibits the extrinsic apoptotic pathway by targeting FAS; Bioinformatic analysis combining with validation experiments identified FAS as a direct target of miR-106a; Moreover a significant inverse correlation was found between miR-106a and FAS expression not only in gastric cancer cell lines but also in gastric cancer specimens; Taken together these findings suggest that ectopicly overexpressed miR-106a may play an oncogenic role in gastric carcinogenesis and impair extrinsic apoptotic pathway through targeting FAS;Functional experiment ascertained that miR-106a interacted with FAS and mediated caspase3 pathway |
148 | hsa-miR-361-5p | FAS | 0.01 | 0.9852 | -0.34 | 0.58934 | miRanda | -0.33 | 0.00172 | NA | |
149 | hsa-miR-590-5p | FAS | 1.51 | 0.00239 | -0.34 | 0.58934 | miRanda | -0.2 | 0.00636 | NA | |
150 | hsa-let-7e-5p | FASLG | -0.11 | 0.81474 | 1.93 | 0.09085 | miRNATAP | -0.31 | 0.02416 | NA |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | POSITIVE REGULATION OF RESPONSE TO STIMULUS | 48 | 1929 | 3.965e-34 | 1.845e-30 |
2 | INTRACELLULAR SIGNAL TRANSDUCTION | 44 | 1572 | 1.267e-32 | 2.948e-29 |
3 | CELLULAR RESPONSE TO ORGANIC SUBSTANCE | 45 | 1848 | 6.185e-31 | 9.594e-28 |
4 | EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 19 | 99 | 5.045e-29 | 5.868e-26 |
5 | REGULATION OF CELL DEATH | 40 | 1472 | 1.668e-28 | 1.552e-25 |
6 | POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS | 40 | 1492 | 2.802e-28 | 2.173e-25 |
7 | CELL DEATH | 35 | 1001 | 4.883e-28 | 3.246e-25 |
8 | POSITIVE REGULATION OF CELL COMMUNICATION | 40 | 1532 | 7.735e-28 | 4.499e-25 |
9 | POSITIVE REGULATION OF MOLECULAR FUNCTION | 42 | 1791 | 1.115e-27 | 5.763e-25 |
10 | POSITIVE REGULATION OF I KAPPAB KINASE NF KAPPAB SIGNALING | 21 | 179 | 2.656e-27 | 1.124e-24 |
11 | RESPONSE TO CYTOKINE | 31 | 714 | 2.543e-27 | 1.124e-24 |
12 | REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 40 | 1656 | 1.515e-26 | 5.876e-24 |
13 | REGULATION OF I KAPPAB KINASE NF KAPPAB SIGNALING | 22 | 233 | 1.797e-26 | 6.432e-24 |
14 | NEGATIVE REGULATION OF CELL DEATH | 32 | 872 | 5.232e-26 | 1.739e-23 |
15 | APOPTOTIC SIGNALING PATHWAY | 23 | 289 | 5.906e-26 | 1.754e-23 |
16 | POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 32 | 876 | 6.031e-26 | 1.754e-23 |
17 | RESPONSE TO OXYGEN CONTAINING COMPOUND | 37 | 1381 | 9.299e-26 | 2.545e-23 |
18 | IMMUNE SYSTEM PROCESS | 41 | 1984 | 9.968e-25 | 2.577e-22 |
19 | EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS | 13 | 39 | 1.473e-23 | 3.608e-21 |
20 | REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 19 | 213 | 2.258e-22 | 5.254e-20 |
21 | POSITIVE REGULATION OF CATALYTIC ACTIVITY | 35 | 1518 | 5.444e-22 | 1.206e-19 |
22 | REGULATION OF IMMUNE SYSTEM PROCESS | 34 | 1403 | 5.855e-22 | 1.238e-19 |
23 | ACTIVATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 15 | 95 | 1.259e-21 | 2.547e-19 |
24 | NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 15 | 98 | 2.069e-21 | 4.011e-19 |
25 | CELLULAR RESPONSE TO CYTOKINE STIMULUS | 25 | 606 | 3.395e-21 | 6.318e-19 |
26 | RESPONSE TO NITROGEN COMPOUND | 28 | 859 | 4.091e-21 | 7.321e-19 |
27 | CELLULAR RESPONSE TO OXYGEN CONTAINING COMPOUND | 27 | 799 | 1.021e-20 | 1.76e-18 |
28 | ZYMOGEN ACTIVATION | 15 | 112 | 1.717e-20 | 2.854e-18 |
29 | REGULATION OF IMMUNE RESPONSE | 27 | 858 | 6.405e-20 | 1.028e-17 |
30 | POSITIVE REGULATION OF IMMUNE RESPONSE | 23 | 563 | 2.339e-19 | 3.628e-17 |
31 | RESPONSE TO MOLECULE OF BACTERIAL ORIGIN | 19 | 321 | 5.665e-19 | 8.503e-17 |
32 | CYTOKINE MEDIATED SIGNALING PATHWAY | 21 | 452 | 8.576e-19 | 1.247e-16 |
33 | POSITIVE REGULATION OF CELL DEATH | 23 | 605 | 1.154e-18 | 1.627e-16 |
34 | POSITIVE REGULATION OF IMMUNE SYSTEM PROCESS | 26 | 867 | 1.257e-18 | 1.721e-16 |
35 | REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 15 | 153 | 2.194e-18 | 2.917e-16 |
36 | POSITIVE REGULATION OF PEPTIDASE ACTIVITY | 15 | 154 | 2.425e-18 | 3.135e-16 |
37 | REGULATION OF RESPONSE TO STRESS | 31 | 1468 | 4.522e-18 | 5.687e-16 |
38 | ACTIVATION OF IMMUNE RESPONSE | 20 | 427 | 5.742e-18 | 7.031e-16 |
39 | POSITIVE REGULATION OF DEFENSE RESPONSE | 19 | 364 | 5.965e-18 | 7.117e-16 |
40 | POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 28 | 1135 | 6.464e-18 | 7.519e-16 |
41 | REGULATION OF PHOSPHORUS METABOLIC PROCESS | 32 | 1618 | 6.936e-18 | 7.871e-16 |
42 | POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 27 | 1036 | 7.802e-18 | 8.443e-16 |
43 | POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 27 | 1036 | 7.802e-18 | 8.443e-16 |
44 | CELLULAR RESPONSE TO NITROGEN COMPOUND | 21 | 505 | 8.215e-18 | 8.688e-16 |
45 | POSITIVE REGULATION OF NF KAPPAB TRANSCRIPTION FACTOR ACTIVITY | 14 | 132 | 1.069e-17 | 1.105e-15 |
46 | PROTEIN MATURATION | 17 | 265 | 1.333e-17 | 1.348e-15 |
47 | REGULATION OF KINASE ACTIVITY | 24 | 776 | 1.918e-17 | 1.899e-15 |
48 | REGULATION OF PEPTIDASE ACTIVITY | 19 | 392 | 2.366e-17 | 2.293e-15 |
49 | RESPONSE TO BIOTIC STIMULUS | 25 | 886 | 2.951e-17 | 2.802e-15 |
50 | POSITIVE REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY | 16 | 228 | 3.217e-17 | 2.994e-15 |
51 | RESPONSE TO ENDOGENOUS STIMULUS | 30 | 1450 | 3.492e-17 | 3.186e-15 |
52 | REGULATION OF PROTEOLYSIS | 23 | 711 | 4.003e-17 | 3.581e-15 |
53 | POSITIVE REGULATION OF KINASE ACTIVITY | 20 | 482 | 6.02e-17 | 5.285e-15 |
54 | RESPONSE TO ABIOTIC STIMULUS | 26 | 1024 | 7.301e-17 | 6.291e-15 |
55 | REGULATION OF APOPTOTIC SIGNALING PATHWAY | 18 | 363 | 1.252e-16 | 1.059e-14 |
56 | PROTEIN PHOSPHORYLATION | 25 | 944 | 1.302e-16 | 1.063e-14 |
57 | NEGATIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY | 15 | 200 | 1.29e-16 | 1.063e-14 |
58 | REGULATION OF TRANSFERASE ACTIVITY | 25 | 946 | 1.368e-16 | 1.097e-14 |
59 | ACTIVATION OF INNATE IMMUNE RESPONSE | 15 | 204 | 1.737e-16 | 1.37e-14 |
60 | REGULATION OF PROTEIN MODIFICATION PROCESS | 31 | 1710 | 3.399e-16 | 2.636e-14 |
61 | RESPONSE TO BACTERIUM | 20 | 528 | 3.475e-16 | 2.65e-14 |
62 | I KAPPAB KINASE NF KAPPAB SIGNALING | 11 | 70 | 4.669e-16 | 3.504e-14 |
63 | PHOSPHORYLATION | 27 | 1228 | 5.489e-16 | 4.054e-14 |
64 | ACTIVATION OF PROTEIN KINASE ACTIVITY | 16 | 279 | 7.944e-16 | 5.776e-14 |
65 | RESPONSE TO TUMOR NECROSIS FACTOR | 15 | 233 | 1.27e-15 | 9.093e-14 |
66 | PATTERN RECOGNITION RECEPTOR SIGNALING PATHWAY | 12 | 109 | 1.722e-15 | 1.214e-13 |
67 | RESPONSE TO EXTERNAL STIMULUS | 31 | 1821 | 1.967e-15 | 1.366e-13 |
68 | POSITIVE REGULATION OF PROTEOLYSIS | 17 | 363 | 2.561e-15 | 1.753e-13 |
69 | POSITIVE REGULATION OF INNATE IMMUNE RESPONSE | 15 | 246 | 2.847e-15 | 1.92e-13 |
70 | TOLL LIKE RECEPTOR SIGNALING PATHWAY | 11 | 85 | 4.429e-15 | 2.944e-13 |
71 | ACTIVATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 7 | 13 | 5.79e-15 | 3.795e-13 |
72 | INFLAMMATORY RESPONSE | 18 | 454 | 6.175e-15 | 3.991e-13 |
73 | POSITIVE REGULATION OF TRANSFERASE ACTIVITY | 20 | 616 | 6.53e-15 | 4.162e-13 |
74 | IMMUNE RESPONSE REGULATING CELL SURFACE RECEPTOR SIGNALING PATHWAY | 16 | 323 | 7.898e-15 | 4.966e-13 |
75 | REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 18 | 470 | 1.122e-14 | 6.962e-13 |
76 | PHOSPHATE CONTAINING COMPOUND METABOLIC PROCESS | 31 | 1977 | 1.903e-14 | 1.165e-12 |
77 | REGULATION OF DEFENSE RESPONSE | 21 | 759 | 2.774e-14 | 1.677e-12 |
78 | NUCLEOTIDE BINDING DOMAIN LEUCINE RICH REPEAT CONTAINING RECEPTOR SIGNALING PATHWAY | 8 | 28 | 3.034e-14 | 1.81e-12 |
79 | REGULATION OF INNATE IMMUNE RESPONSE | 16 | 357 | 3.74e-14 | 2.203e-12 |
80 | FC EPSILON RECEPTOR SIGNALING PATHWAY | 12 | 142 | 4.396e-14 | 2.557e-12 |
81 | REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY | 16 | 365 | 5.268e-14 | 2.99e-12 |
82 | REGULATION OF RESPONSE TO CYTOKINE STIMULUS | 12 | 144 | 5.208e-14 | 2.99e-12 |
83 | RESPONSE TO LIPID | 22 | 888 | 5.496e-14 | 3.081e-12 |
84 | POSITIVE REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 7 | 17 | 6.493e-14 | 3.597e-12 |
85 | REGULATION OF TUMOR NECROSIS FACTOR MEDIATED SIGNALING PATHWAY | 9 | 50 | 6.833e-14 | 3.74e-12 |
86 | REGULATION OF NEURON DEATH | 14 | 252 | 9.569e-14 | 5.177e-12 |
87 | INTRINSIC APOPTOTIC SIGNALING PATHWAY | 12 | 152 | 1.001e-13 | 5.356e-12 |
88 | CELLULAR RESPONSE TO MECHANICAL STIMULUS | 10 | 80 | 1.209e-13 | 6.393e-12 |
89 | SIGNAL TRANSDUCTION IN ABSENCE OF LIGAND | 8 | 33 | 1.337e-13 | 6.839e-12 |
90 | EXTRINSIC APOPTOTIC SIGNALING PATHWAY IN ABSENCE OF LIGAND | 8 | 33 | 1.337e-13 | 6.839e-12 |
91 | CYTOPLASMIC PATTERN RECOGNITION RECEPTOR SIGNALING PATHWAY | 8 | 33 | 1.337e-13 | 6.839e-12 |
92 | CELLULAR RESPONSE TO ABIOTIC STIMULUS | 14 | 263 | 1.72e-13 | 8.698e-12 |
93 | NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS | 8 | 34 | 1.744e-13 | 8.728e-12 |
94 | CELLULAR RESPONSE TO STRESS | 27 | 1565 | 2.034e-13 | 1.007e-11 |
95 | POSITIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY | 12 | 171 | 4.125e-13 | 2.02e-11 |
96 | REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 7 | 22 | 5.62e-13 | 2.724e-11 |
97 | RESPONSE TO HORMONE | 21 | 893 | 6.482e-13 | 3.109e-11 |
98 | CELLULAR RESPONSE TO ENDOGENOUS STIMULUS | 22 | 1008 | 7.041e-13 | 3.343e-11 |
99 | FC RECEPTOR SIGNALING PATHWAY | 12 | 206 | 3.773e-12 | 1.773e-10 |
100 | RESPONSE TO PEPTIDE | 15 | 404 | 3.904e-12 | 1.816e-10 |
101 | IMMUNE RESPONSE | 22 | 1100 | 3.984e-12 | 1.836e-10 |
102 | REGULATION OF CELL PROLIFERATION | 25 | 1496 | 4.494e-12 | 2.05e-10 |
103 | RESPONSE TO MECHANICAL STIMULUS | 12 | 210 | 4.734e-12 | 2.139e-10 |
104 | TUMOR NECROSIS FACTOR MEDIATED SIGNALING PATHWAY | 10 | 118 | 6.483e-12 | 2.901e-10 |
105 | RESPONSE TO ORGANIC CYCLIC COMPOUND | 20 | 917 | 1.03e-11 | 4.563e-10 |
106 | REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS | 8 | 55 | 1.107e-11 | 4.859e-10 |
107 | POSITIVE REGULATION OF GENE EXPRESSION | 26 | 1733 | 1.632e-11 | 7.096e-10 |
108 | REGULATION OF CATABOLIC PROCESS | 18 | 731 | 1.925e-11 | 8.292e-10 |
109 | NEURON APOPTOTIC PROCESS | 7 | 35 | 2.141e-11 | 9.141e-10 |
110 | HOMEOSTATIC PROCESS | 23 | 1337 | 2.416e-11 | 1.022e-09 |
111 | CELLULAR RESPONSE TO ORGANIC CYCLIC COMPOUND | 15 | 465 | 2.864e-11 | 1.201e-09 |
112 | WOUND HEALING | 15 | 470 | 3.329e-11 | 1.383e-09 |
113 | NEGATIVE REGULATION OF RESPONSE TO STIMULUS | 23 | 1360 | 3.407e-11 | 1.403e-09 |
114 | RESPONSE TO WOUNDING | 16 | 563 | 3.751e-11 | 1.531e-09 |
115 | RESPONSE TO INORGANIC SUBSTANCE | 15 | 479 | 4.346e-11 | 1.758e-09 |
116 | ANTIGEN RECEPTOR MEDIATED SIGNALING PATHWAY | 11 | 195 | 4.554e-11 | 1.827e-09 |
117 | T CELL RECEPTOR SIGNALING PATHWAY | 10 | 146 | 5.473e-11 | 2.177e-09 |
118 | CELLULAR RESPONSE TO EXTERNAL STIMULUS | 12 | 264 | 6.865e-11 | 2.707e-09 |
119 | POSITIVE REGULATION OF HYDROLASE ACTIVITY | 19 | 905 | 7.33e-11 | 2.866e-09 |
120 | INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO DNA DAMAGE | 8 | 71 | 9.275e-11 | 3.596e-09 |
121 | CELLULAR RESPONSE TO PEPTIDE | 12 | 274 | 1.055e-10 | 4.058e-09 |
122 | RESPONSE TO AMINO ACID | 9 | 112 | 1.274e-10 | 4.859e-09 |
123 | NEGATIVE REGULATION OF CELL COMMUNICATION | 21 | 1192 | 1.489e-10 | 5.633e-09 |
124 | REGULATION OF HYDROLASE ACTIVITY | 22 | 1327 | 1.529e-10 | 5.739e-09 |
125 | RESPONSE TO INTERLEUKIN 1 | 9 | 115 | 1.618e-10 | 6.022e-09 |
126 | REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY IN ABSENCE OF LIGAND | 7 | 46 | 1.656e-10 | 6.115e-09 |
127 | POSITIVE REGULATION OF CELLULAR PROTEIN LOCALIZATION | 13 | 360 | 1.773e-10 | 6.495e-09 |
128 | PROTEOLYSIS | 21 | 1208 | 1.903e-10 | 6.917e-09 |
129 | NEURON DEATH | 7 | 47 | 1.941e-10 | 7e-09 |
130 | PHOSPHATIDYLINOSITOL 3 PHOSPHATE BIOSYNTHETIC PROCESS | 7 | 49 | 2.637e-10 | 9.437e-09 |
131 | DEFENSE RESPONSE | 21 | 1231 | 2.69e-10 | 9.554e-09 |
132 | CELLULAR RESPONSE TO HORMONE STIMULUS | 15 | 552 | 3.134e-10 | 1.096e-08 |
133 | REGULATION OF CELLULAR PROTEIN LOCALIZATION | 15 | 552 | 3.134e-10 | 1.096e-08 |
134 | CHEMICAL HOMEOSTASIS | 18 | 874 | 3.524e-10 | 1.224e-08 |
135 | INTERLEUKIN 1 MEDIATED SIGNALING PATHWAY | 5 | 13 | 4.568e-10 | 1.574e-08 |
136 | CELLULAR RESPONSE TO INTERLEUKIN 1 | 8 | 88 | 5.359e-10 | 1.833e-08 |
137 | RESPONSE TO ACID CHEMICAL | 12 | 319 | 6.037e-10 | 2.036e-08 |
138 | REGULATION OF MAP KINASE ACTIVITY | 12 | 319 | 6.037e-10 | 2.036e-08 |
139 | EXECUTION PHASE OF APOPTOSIS | 7 | 55 | 6.131e-10 | 2.052e-08 |
140 | LIPOPOLYSACCHARIDE MEDIATED SIGNALING PATHWAY | 6 | 31 | 7.748e-10 | 2.575e-08 |
141 | NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY IN ABSENCE OF LIGAND | 6 | 32 | 9.511e-10 | 3.117e-08 |
142 | NEGATIVE REGULATION OF SIGNAL TRANSDUCTION IN ABSENCE OF LIGAND | 6 | 32 | 9.511e-10 | 3.117e-08 |
143 | POSITIVE REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION | 14 | 514 | 1.292e-09 | 4.203e-08 |
144 | NEGATIVE REGULATION OF CATABOLIC PROCESS | 10 | 203 | 1.394e-09 | 4.504e-08 |
145 | NEGATIVE REGULATION OF MOLECULAR FUNCTION | 19 | 1079 | 1.412e-09 | 4.53e-08 |
146 | POSITIVE REGULATION OF BIOSYNTHETIC PROCESS | 24 | 1805 | 1.554e-09 | 4.953e-08 |
147 | RESPONSE TO OXIDATIVE STRESS | 12 | 352 | 1.844e-09 | 5.836e-08 |
148 | STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE | 8 | 103 | 1.905e-09 | 5.991e-08 |
149 | ACTIVATION OF PROTEIN KINASE A ACTIVITY | 5 | 17 | 2.174e-09 | 6.788e-08 |
150 | INNATE IMMUNE RESPONSE ACTIVATING CELL SURFACE RECEPTOR SIGNALING PATHWAY | 8 | 106 | 2.398e-09 | 7.438e-08 |
151 | POSITIVE REGULATION OF NEURON DEATH | 7 | 67 | 2.546e-09 | 7.845e-08 |
152 | POSITIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 11 | 289 | 2.974e-09 | 9.104e-08 |
153 | POSITIVE REGULATION OF INTRACELLULAR TRANSPORT | 12 | 370 | 3.233e-09 | 9.831e-08 |
154 | REGULATION OF MAPK CASCADE | 15 | 660 | 3.604e-09 | 1.089e-07 |
155 | CELLULAR RESPONSE TO BIOTIC STIMULUS | 9 | 163 | 3.626e-09 | 1.089e-07 |
156 | POSITIVE REGULATION OF MAPK CASCADE | 13 | 470 | 4.517e-09 | 1.347e-07 |
157 | RESPONSE TO CARBOHYDRATE | 9 | 168 | 4.73e-09 | 1.402e-07 |
158 | CELLULAR RESPONSE TO CARBOHYDRATE STIMULUS | 7 | 74 | 5.172e-09 | 1.523e-07 |
159 | GLUCOSE HOMEOSTASIS | 9 | 170 | 5.247e-09 | 1.526e-07 |
160 | CARBOHYDRATE HOMEOSTASIS | 9 | 170 | 5.247e-09 | 1.526e-07 |
161 | CELLULAR GLUCOSE HOMEOSTASIS | 7 | 75 | 5.69e-09 | 1.644e-07 |
162 | RESPONSE TO OXYGEN LEVELS | 11 | 311 | 6.384e-09 | 1.822e-07 |
163 | HEMOSTASIS | 11 | 311 | 6.384e-09 | 1.822e-07 |
164 | PHOSPHATIDYLINOSITOL BIOSYNTHETIC PROCESS | 8 | 120 | 6.44e-09 | 1.827e-07 |
165 | POSITIVE REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 8 | 121 | 6.877e-09 | 1.939e-07 |
166 | INOSITOL LIPID MEDIATED SIGNALING | 8 | 124 | 8.349e-09 | 2.34e-07 |
167 | REGULATION OF PROTEIN LOCALIZATION | 17 | 950 | 9.894e-09 | 2.757e-07 |
168 | POSITIVE REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS | 8 | 129 | 1.141e-08 | 3.16e-07 |
169 | NIK NF KAPPAB SIGNALING | 7 | 83 | 1.165e-08 | 3.209e-07 |
170 | RESPONSE TO REACTIVE OXYGEN SPECIES | 9 | 191 | 1.451e-08 | 3.972e-07 |
171 | REGULATION OF NEURON APOPTOTIC PROCESS | 9 | 192 | 1.519e-08 | 4.132e-07 |
172 | REGULATION OF CELL ADHESION | 14 | 629 | 1.686e-08 | 4.561e-07 |
173 | POSITIVE REGULATION OF TRANSCRIPTION FACTOR IMPORT INTO NUCLEUS | 6 | 51 | 1.799e-08 | 4.81e-07 |
174 | RESPONSE TO NICOTINE | 6 | 51 | 1.799e-08 | 4.81e-07 |
175 | RESPONSE TO ALKALOID | 8 | 137 | 1.832e-08 | 4.842e-07 |
176 | PHOSPHATIDYLINOSITOL 3 KINASE SIGNALING | 5 | 25 | 1.828e-08 | 4.842e-07 |
177 | POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 17 | 1004 | 2.235e-08 | 5.875e-07 |
178 | REGULATION OF NECROTIC CELL DEATH | 5 | 26 | 2.257e-08 | 5.901e-07 |
179 | POSITIVE REGULATION OF MAP KINASE ACTIVITY | 9 | 207 | 2.914e-08 | 7.574e-07 |
180 | REGULATION OF TRANSCRIPTION FACTOR IMPORT INTO NUCLEUS | 7 | 95 | 3.005e-08 | 7.769e-07 |
181 | REGULATION OF LIPID METABOLIC PROCESS | 10 | 282 | 3.235e-08 | 8.317e-07 |
182 | PEPTIDYL SERINE MODIFICATION | 8 | 148 | 3.353e-08 | 8.572e-07 |
183 | CELLULAR RESPONSE TO LIPID | 12 | 457 | 3.372e-08 | 8.574e-07 |
184 | POSITIVE REGULATION OF NFAT PROTEIN IMPORT INTO NUCLEUS | 4 | 11 | 3.729e-08 | 9.429e-07 |
185 | CELL ACTIVATION | 13 | 568 | 4.247e-08 | 1.068e-06 |
186 | REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS | 9 | 218 | 4.552e-08 | 1.139e-06 |
187 | REGULATION OF INFLAMMATORY RESPONSE | 10 | 294 | 4.788e-08 | 1.191e-06 |
188 | MYD88 INDEPENDENT TOLL LIKE RECEPTOR SIGNALING PATHWAY | 5 | 30 | 4.84e-08 | 1.198e-06 |
189 | REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 9 | 220 | 4.924e-08 | 1.208e-06 |
190 | RENAL SYSTEM PROCESS | 7 | 102 | 4.931e-08 | 1.208e-06 |
191 | REGULATION OF ENDOTHELIAL CELL DEVELOPMENT | 4 | 12 | 5.579e-08 | 1.345e-06 |
192 | REGULATION OF ESTABLISHMENT OF ENDOTHELIAL BARRIER | 4 | 12 | 5.579e-08 | 1.345e-06 |
193 | POSITIVE REGULATION OF TRANSPORT | 16 | 936 | 5.536e-08 | 1.345e-06 |
194 | POSITIVE REGULATION OF PROTEIN IMPORT | 7 | 104 | 5.642e-08 | 1.353e-06 |
195 | REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT | 21 | 1672 | 6.215e-08 | 1.483e-06 |
196 | REGULATION OF CELL ACTIVATION | 12 | 484 | 6.315e-08 | 1.499e-06 |
197 | MYD88 DEPENDENT TOLL LIKE RECEPTOR SIGNALING PATHWAY | 5 | 32 | 6.805e-08 | 1.599e-06 |
198 | INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO ENDOPLASMIC RETICULUM STRESS | 5 | 32 | 6.805e-08 | 1.599e-06 |
199 | NEGATIVE REGULATION OF PROTEIN METABOLIC PROCESS | 17 | 1087 | 7.103e-08 | 1.661e-06 |
200 | NEGATIVE REGULATION OF CATALYTIC ACTIVITY | 15 | 829 | 7.45e-08 | 1.733e-06 |
201 | RESPONSE TO COBALT ION | 4 | 13 | 8.038e-08 | 1.861e-06 |
202 | INTRACELLULAR RECEPTOR SIGNALING PATHWAY | 8 | 168 | 8.976e-08 | 2.068e-06 |
203 | T CELL HOMEOSTASIS | 5 | 34 | 9.354e-08 | 2.103e-06 |
204 | PROTEIN KINASE B SIGNALING | 5 | 34 | 9.354e-08 | 2.103e-06 |
205 | RENAL WATER HOMEOSTASIS | 5 | 34 | 9.354e-08 | 2.103e-06 |
206 | SIGNAL TRANSDUCTION BY PROTEIN PHOSPHORYLATION | 11 | 404 | 9.292e-08 | 2.103e-06 |
207 | CELLULAR RESPONSE TO ALKALOID | 5 | 34 | 9.354e-08 | 2.103e-06 |
208 | RESPONSE TO TOXIC SUBSTANCE | 9 | 241 | 1.074e-07 | 2.403e-06 |
209 | TOLL LIKE RECEPTOR 9 SIGNALING PATHWAY | 4 | 14 | 1.123e-07 | 2.499e-06 |
210 | REGULATION OF INTRACELLULAR TRANSPORT | 13 | 621 | 1.197e-07 | 2.651e-06 |
211 | RESPONSE TO CORTICOSTEROID | 8 | 176 | 1.285e-07 | 2.834e-06 |
212 | RESPONSE TO VIRUS | 9 | 247 | 1.324e-07 | 2.906e-06 |
213 | RESPONSE TO METAL ION | 10 | 333 | 1.531e-07 | 3.328e-06 |
214 | T CELL APOPTOTIC PROCESS | 4 | 15 | 1.527e-07 | 3.328e-06 |
215 | RESPONSE TO KETONE | 8 | 182 | 1.663e-07 | 3.597e-06 |
216 | CELLULAR RESPONSE TO GLUCAGON STIMULUS | 5 | 38 | 1.67e-07 | 3.597e-06 |
217 | REGULATION OF EPITHELIAL CELL DIFFERENTIATION | 7 | 122 | 1.697e-07 | 3.639e-06 |
218 | REGULATION OF PROTEIN IMPORT | 8 | 183 | 1.735e-07 | 3.687e-06 |
219 | LEUKOCYTE CELL CELL ADHESION | 9 | 255 | 1.736e-07 | 3.687e-06 |
220 | RESPONSE TO DRUG | 11 | 431 | 1.78e-07 | 3.765e-06 |
221 | POSITIVE REGULATION OF INTRACELLULAR PROTEIN TRANSPORT | 9 | 258 | 1.916e-07 | 4.035e-06 |
222 | REGULATION OF ORGANELLE ORGANIZATION | 17 | 1178 | 2.247e-07 | 4.709e-06 |
223 | AGING | 9 | 264 | 2.327e-07 | 4.856e-06 |
224 | PHOSPHATIDYLINOSITOL METABOLIC PROCESS | 8 | 193 | 2.607e-07 | 5.415e-06 |
225 | REGULATION OF NFAT PROTEIN IMPORT INTO NUCLEUS | 4 | 17 | 2.649e-07 | 5.478e-06 |
226 | REGULATION OF NIK NF KAPPAB SIGNALING | 5 | 42 | 2.801e-07 | 5.767e-06 |
227 | MULTICELLULAR ORGANISMAL HOMEOSTASIS | 9 | 272 | 2.994e-07 | 6.137e-06 |
228 | CELLULAR COMPONENT DISASSEMBLY INVOLVED IN EXECUTION PHASE OF APOPTOSIS | 5 | 43 | 3.161e-07 | 6.452e-06 |
229 | LYMPHOCYTE APOPTOTIC PROCESS | 4 | 18 | 3.397e-07 | 6.902e-06 |
230 | POSITIVE REGULATION OF CELL PROLIFERATION | 14 | 814 | 4.027e-07 | 8.146e-06 |
231 | IMMUNE SYSTEM DEVELOPMENT | 12 | 582 | 4.587e-07 | 9.239e-06 |
232 | POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 18 | 1395 | 4.787e-07 | 9.601e-06 |
233 | NEGATIVE REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 6 | 88 | 4.913e-07 | 9.811e-06 |
234 | POSITIVE REGULATION OF NEURON APOPTOTIC PROCESS | 5 | 47 | 4.986e-07 | 9.915e-06 |
235 | GLYCEROLIPID BIOSYNTHETIC PROCESS | 8 | 211 | 5.139e-07 | 1.016e-05 |
236 | REGULATION OF CELL CELL ADHESION | 10 | 380 | 5.155e-07 | 1.016e-05 |
237 | REGULATION OF INTRACELLULAR PROTEIN TRANSPORT | 10 | 381 | 5.28e-07 | 1.037e-05 |
238 | LEUKOCYTE DIFFERENTIATION | 9 | 292 | 5.429e-07 | 1.061e-05 |
239 | RESPONSE TO GLUCAGON | 5 | 48 | 5.552e-07 | 1.081e-05 |
240 | RESPONSE TO TEMPERATURE STIMULUS | 7 | 148 | 6.322e-07 | 1.226e-05 |
241 | NEGATIVE REGULATION OF LIPID CATABOLIC PROCESS | 4 | 21 | 6.594e-07 | 1.27e-05 |
242 | CELL DEVELOPMENT | 18 | 1426 | 6.604e-07 | 1.27e-05 |
243 | LYMPHOCYTE HOMEOSTASIS | 5 | 50 | 6.834e-07 | 1.309e-05 |
244 | REGULATION OF CELLULAR LOCALIZATION | 17 | 1277 | 6.991e-07 | 1.333e-05 |
245 | REGULATION OF HOMOTYPIC CELL CELL ADHESION | 9 | 307 | 8.243e-07 | 1.559e-05 |
246 | REGULATION OF PROTEIN TARGETING | 9 | 307 | 8.243e-07 | 1.559e-05 |
247 | REGULATION OF LIPID CATABOLIC PROCESS | 5 | 52 | 8.34e-07 | 1.571e-05 |
248 | REGULATION OF BODY FLUID LEVELS | 11 | 506 | 8.718e-07 | 1.636e-05 |
249 | REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 20 | 1784 | 8.78e-07 | 1.641e-05 |
250 | LEUKOCYTE APOPTOTIC PROCESS | 4 | 23 | 9.707e-07 | 1.807e-05 |
251 | LIPID PHOSPHORYLATION | 6 | 99 | 9.87e-07 | 1.83e-05 |
252 | REGULATION OF GLUCOSE TRANSPORT | 6 | 100 | 1.047e-06 | 1.926e-05 |
253 | REGULATION OF TRANSPORT | 20 | 1804 | 1.047e-06 | 1.926e-05 |
254 | REGULATION OF RESPONSE TO WOUNDING | 10 | 413 | 1.098e-06 | 2.003e-05 |
255 | RESPONSE TO RADIATION | 10 | 413 | 1.098e-06 | 2.003e-05 |
256 | PHOSPHOLIPID BIOSYNTHETIC PROCESS | 8 | 235 | 1.158e-06 | 2.104e-05 |
257 | REGULATION OF EXECUTION PHASE OF APOPTOSIS | 4 | 24 | 1.162e-06 | 2.104e-05 |
258 | REGULATION OF CELL DIFFERENTIATION | 18 | 1492 | 1.273e-06 | 2.296e-05 |
259 | MULTICELLULAR ORGANISMAL WATER HOMEOSTASIS | 5 | 58 | 1.448e-06 | 2.601e-05 |
260 | POSITIVE REGULATION OF CELL CELL ADHESION | 8 | 243 | 1.488e-06 | 2.663e-05 |
261 | REGULATION OF CELLULAR RESPONSE TO INSULIN STIMULUS | 5 | 59 | 1.578e-06 | 2.813e-05 |
262 | NEGATIVE REGULATION OF NEURON DEATH | 7 | 171 | 1.668e-06 | 2.963e-05 |
263 | REGULATION OF GLUCOSE IMPORT | 5 | 60 | 1.717e-06 | 3.026e-05 |
264 | LEUKOCYTE HOMEOSTASIS | 5 | 60 | 1.717e-06 | 3.026e-05 |
265 | RESPONSE TO HYDROGEN PEROXIDE | 6 | 109 | 1.738e-06 | 3.051e-05 |
266 | REGULATION OF AUTOPHAGY | 8 | 249 | 1.785e-06 | 3.123e-05 |
267 | REGULATION OF ENDOTHELIAL CELL DIFFERENTIATION | 4 | 27 | 1.905e-06 | 3.307e-05 |
268 | DNA CATABOLIC PROCESS | 4 | 27 | 1.905e-06 | 3.307e-05 |
269 | LYMPHOCYTE ACTIVATION | 9 | 342 | 2.011e-06 | 3.479e-05 |
270 | CELLULAR HOMEOSTASIS | 12 | 676 | 2.203e-06 | 3.796e-05 |
271 | NECROTIC CELL DEATH | 4 | 28 | 2.216e-06 | 3.806e-05 |
272 | LEUKOCYTE MIGRATION | 8 | 259 | 2.394e-06 | 4.095e-05 |
273 | REGULATION OF CYTOKINE PRODUCTION | 11 | 563 | 2.459e-06 | 4.19e-05 |
274 | NEGATIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 12 | 684 | 2.488e-06 | 4.225e-05 |
275 | REGULATION OF PROTEIN INSERTION INTO MITOCHONDRIAL MEMBRANE INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 4 | 29 | 2.565e-06 | 4.308e-05 |
276 | POSITIVE REGULATION OF PROTEIN INSERTION INTO MITOCHONDRIAL MEMBRANE INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 4 | 29 | 2.565e-06 | 4.308e-05 |
277 | POSITIVE REGULATION OF NIK NF KAPPAB SIGNALING | 4 | 29 | 2.565e-06 | 4.308e-05 |
278 | ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS | 14 | 957 | 2.74e-06 | 4.586e-05 |
279 | CELLULAR CHEMICAL HOMEOSTASIS | 11 | 570 | 2.769e-06 | 4.618e-05 |
280 | SINGLE ORGANISM CELL ADHESION | 10 | 459 | 2.829e-06 | 4.702e-05 |
281 | MYELOID CELL DIFFERENTIATION | 7 | 189 | 3.245e-06 | 5.373e-05 |
282 | WATER HOMEOSTASIS | 5 | 70 | 3.707e-06 | 6.095e-05 |
283 | REGULATION OF MEMBRANE PERMEABILITY | 5 | 70 | 3.707e-06 | 6.095e-05 |
284 | POSITIVE REGULATION OF CYTOKINE PRODUCTION | 9 | 370 | 3.824e-06 | 6.266e-05 |
285 | NEGATIVE REGULATION OF IMMUNE SYSTEM PROCESS | 9 | 372 | 3.996e-06 | 6.523e-05 |
286 | RESPONSE TO UV | 6 | 126 | 4.042e-06 | 6.554e-05 |
287 | NEGATIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 6 | 126 | 4.042e-06 | 6.554e-05 |
288 | CELLULAR RESPONSE TO DNA DAMAGE STIMULUS | 12 | 720 | 4.214e-06 | 6.808e-05 |
289 | REGULATION OF CYTOPLASMIC TRANSPORT | 10 | 481 | 4.285e-06 | 6.898e-05 |
290 | POSITIVE REGULATION OF CYTOPLASMIC TRANSPORT | 8 | 282 | 4.49e-06 | 7.204e-05 |
291 | POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 15 | 1152 | 4.745e-06 | 7.588e-05 |
292 | RESPONSE TO STEROID HORMONE | 10 | 497 | 5.716e-06 | 9.109e-05 |
293 | POSITIVE REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 4 | 36 | 6.249e-06 | 9.924e-05 |
294 | GLYCEROPHOSPHOLIPID METABOLIC PROCESS | 8 | 297 | 6.567e-06 | 0.0001036 |
295 | ACTIVATION OF MAPK ACTIVITY | 6 | 137 | 6.554e-06 | 0.0001036 |
296 | NEGATIVE REGULATION OF LIPID METABOLIC PROCESS | 5 | 80 | 7.176e-06 | 0.0001124 |
297 | INSULIN RECEPTOR SIGNALING PATHWAY | 5 | 80 | 7.176e-06 | 0.0001124 |
298 | REGULATION OF VITAMIN METABOLIC PROCESS | 3 | 12 | 7.736e-06 | 0.0001204 |
299 | POSITIVE REGULATION OF GLUCOSE IMPORT IN RESPONSE TO INSULIN STIMULUS | 3 | 12 | 7.736e-06 | 0.0001204 |
300 | PLATELET ACTIVATION | 6 | 142 | 8.053e-06 | 0.0001249 |
301 | JNK CASCADE | 5 | 82 | 8.103e-06 | 0.0001253 |
302 | REGULATION OF MITOCHONDRION ORGANIZATION | 7 | 218 | 8.29e-06 | 0.0001273 |
303 | RESPONSE TO ESTROGEN | 7 | 218 | 8.29e-06 | 0.0001273 |
304 | CELLULAR RESPONSE TO OXYGEN LEVELS | 6 | 143 | 8.384e-06 | 0.0001283 |
305 | POSITIVE REGULATION OF CELL ACTIVATION | 8 | 311 | 9.189e-06 | 0.0001402 |
306 | LEUKOCYTE ACTIVATION | 9 | 414 | 9.463e-06 | 0.0001434 |
307 | RESPONSE TO ESTRADIOL | 6 | 146 | 9.443e-06 | 0.0001434 |
308 | HEPATOCYTE APOPTOTIC PROCESS | 3 | 13 | 1.003e-05 | 0.0001511 |
309 | REGULATION OF BICELLULAR TIGHT JUNCTION ASSEMBLY | 3 | 13 | 1.003e-05 | 0.0001511 |
310 | REGULATION OF RESPONSE TO EXTERNAL STIMULUS | 13 | 926 | 1.026e-05 | 0.0001539 |
311 | POSITIVE REGULATION OF PEPTIDYL SERINE PHOSPHORYLATION | 5 | 88 | 1.146e-05 | 0.0001714 |
312 | POSITIVE REGULATION OF GLUCOSE TRANSPORT | 4 | 42 | 1.17e-05 | 0.0001744 |
313 | RESPONSE TO HEAT | 5 | 89 | 1.211e-05 | 0.00018 |
314 | REGULATION OF CAMP DEPENDENT PROTEIN KINASE ACTIVITY | 3 | 14 | 1.274e-05 | 0.0001888 |
315 | REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 4 | 43 | 1.286e-05 | 0.00019 |
316 | CELL PROLIFERATION | 11 | 672 | 1.317e-05 | 0.0001939 |
317 | NEGATIVE REGULATION OF CELLULAR CATABOLIC PROCESS | 6 | 156 | 1.378e-05 | 0.0002023 |
318 | REGULATION OF RELEASE OF CYTOCHROME C FROM MITOCHONDRIA | 4 | 44 | 1.411e-05 | 0.0002065 |
319 | MITOCHONDRIAL MEMBRANE ORGANIZATION | 5 | 92 | 1.423e-05 | 0.0002076 |
320 | NEGATIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 9 | 437 | 1.456e-05 | 0.0002117 |
321 | REGULATION OF CYTOKINE BIOSYNTHETIC PROCESS | 5 | 94 | 1.58e-05 | 0.0002291 |
322 | APOPTOTIC DNA FRAGMENTATION | 3 | 15 | 1.589e-05 | 0.0002296 |
323 | REGULATION OF LIPID TRANSPORT | 5 | 95 | 1.664e-05 | 0.0002397 |
324 | REGULATION OF CELLULAR RESPONSE TO STRESS | 11 | 691 | 1.706e-05 | 0.0002451 |
325 | RESPONSE TO ANTIBIOTIC | 4 | 47 | 1.841e-05 | 0.0002635 |
326 | POSITIVE REGULATION OF ORGANELLE ORGANIZATION | 10 | 573 | 1.967e-05 | 0.0002807 |
327 | POSITIVE REGULATION OF REACTIVE OXYGEN SPECIES BIOSYNTHETIC PROCESS | 4 | 48 | 2.003e-05 | 0.000285 |
328 | NEGATIVE REGULATION OF KINASE ACTIVITY | 7 | 250 | 2.013e-05 | 0.0002856 |
329 | CELLULAR PROCESS INVOLVED IN REPRODUCTION IN MULTICELLULAR ORGANISM | 7 | 252 | 2.119e-05 | 0.0002997 |
330 | ACTIVATION OF NF KAPPAB INDUCING KINASE ACTIVITY | 3 | 17 | 2.363e-05 | 0.0003301 |
331 | REGULATION OF GLUCOSE IMPORT IN RESPONSE TO INSULIN STIMULUS | 3 | 17 | 2.363e-05 | 0.0003301 |
332 | NEGATIVE REGULATION OF ANOIKIS | 3 | 17 | 2.363e-05 | 0.0003301 |
333 | RESPONSE TO GAMMA RADIATION | 4 | 50 | 2.359e-05 | 0.0003301 |
334 | GLYCEROLIPID METABOLIC PROCESS | 8 | 356 | 2.434e-05 | 0.0003391 |
335 | STRIATED MUSCLE CELL DIFFERENTIATION | 6 | 173 | 2.476e-05 | 0.0003439 |
336 | CELLULAR RESPONSE TO ACID CHEMICAL | 6 | 175 | 2.642e-05 | 0.0003658 |
337 | GAMETE GENERATION | 10 | 595 | 2.714e-05 | 0.0003747 |
338 | RESPONSE TO ALCOHOL | 8 | 362 | 2.742e-05 | 0.0003775 |
339 | RESPONSE TO GROWTH FACTOR | 9 | 475 | 2.808e-05 | 0.0003855 |
340 | NEGATIVE REGULATION OF ORGANIC ACID TRANSPORT | 3 | 18 | 2.828e-05 | 0.000386 |
341 | INOSITOL PHOSPHATE MEDIATED SIGNALING | 3 | 18 | 2.828e-05 | 0.000386 |
342 | PHOSPHOLIPID METABOLIC PROCESS | 8 | 364 | 2.852e-05 | 0.000388 |
343 | REGULATION OF NITRIC OXIDE BIOSYNTHETIC PROCESS | 4 | 53 | 2.977e-05 | 0.0004026 |
344 | CELLULAR RESPONSE TO AMINO ACID STIMULUS | 4 | 53 | 2.977e-05 | 0.0004026 |
345 | CELL CELL ADHESION | 10 | 608 | 3.261e-05 | 0.0004398 |
346 | RESPONSE TO MUSCLE STRETCH | 3 | 19 | 3.351e-05 | 0.0004477 |
347 | NEGATIVE REGULATION OF MEIOTIC CELL CYCLE | 3 | 19 | 3.351e-05 | 0.0004477 |
348 | DNA CATABOLIC PROCESS ENDONUCLEOLYTIC | 3 | 19 | 3.351e-05 | 0.0004477 |
349 | IMMUNE EFFECTOR PROCESS | 9 | 486 | 3.358e-05 | 0.0004477 |
350 | POSITIVE REGULATION OF CELL ADHESION | 8 | 376 | 3.591e-05 | 0.0004773 |
351 | EMBRYO DEVELOPMENT | 12 | 894 | 3.664e-05 | 0.0004857 |
352 | INNATE IMMUNE RESPONSE | 10 | 619 | 3.795e-05 | 0.0005016 |
353 | SINGLE ORGANISM CELLULAR LOCALIZATION | 12 | 898 | 3.827e-05 | 0.0005044 |
354 | APOPTOTIC MITOCHONDRIAL CHANGES | 4 | 57 | 3.975e-05 | 0.0005225 |
355 | POSITIVE REGULATION OF CYTOKINE BIOSYNTHETIC PROCESS | 4 | 58 | 4.259e-05 | 0.0005582 |
356 | PROTEIN AUTOPHOSPHORYLATION | 6 | 192 | 4.442e-05 | 0.0005805 |
357 | MULTICELLULAR ORGANISM REPRODUCTION | 11 | 768 | 4.495e-05 | 0.0005859 |
358 | NECROPTOTIC PROCESS | 3 | 21 | 4.577e-05 | 0.0005932 |
359 | RESPONSE TO NITRIC OXIDE | 3 | 21 | 4.577e-05 | 0.0005932 |
360 | REGULATION OF PEPTIDYL SERINE PHOSPHORYLATION | 5 | 118 | 4.735e-05 | 0.000612 |
361 | REGULATION OF MONOOXYGENASE ACTIVITY | 4 | 60 | 4.87e-05 | 0.0006277 |
362 | GLUCOSE METABOLIC PROCESS | 5 | 119 | 4.93e-05 | 0.0006337 |
363 | GLAND DEVELOPMENT | 8 | 395 | 5.085e-05 | 0.0006518 |
364 | NEGATIVE REGULATION OF HYDROLASE ACTIVITY | 8 | 397 | 5.268e-05 | 0.0006735 |
365 | RELEASE OF CYTOCHROME C FROM MITOCHONDRIA | 3 | 22 | 5.287e-05 | 0.000674 |
366 | REGULATION OF B CELL ACTIVATION | 5 | 121 | 5.339e-05 | 0.0006787 |
367 | POSITIVE REGULATION OF CELLULAR RESPONSE TO INSULIN STIMULUS | 3 | 23 | 6.066e-05 | 0.000769 |
368 | RESPONSE TO INSULIN | 6 | 205 | 6.393e-05 | 0.0008083 |
369 | REGULATION OF CELL CYCLE | 12 | 949 | 6.526e-05 | 0.0008229 |
370 | REGULATION OF REACTIVE OXYGEN SPECIES BIOSYNTHETIC PROCESS | 4 | 65 | 6.677e-05 | 0.0008397 |
371 | REGULATION OF ANOIKIS | 3 | 24 | 6.916e-05 | 0.0008673 |
372 | REGULATION OF LIPID BIOSYNTHETIC PROCESS | 5 | 128 | 6.978e-05 | 0.0008705 |
373 | POSITIVE REGULATION OF LIPID METABOLIC PROCESS | 5 | 128 | 6.978e-05 | 0.0008705 |
374 | POSITIVE REGULATION OF LIPID BIOSYNTHETIC PROCESS | 4 | 66 | 7.09e-05 | 0.0008821 |
375 | LYMPHOCYTE DIFFERENTIATION | 6 | 209 | 7.115e-05 | 0.0008828 |
376 | NUCLEAR IMPORT | 5 | 129 | 7.241e-05 | 0.000896 |
377 | LIPID MODIFICATION | 6 | 210 | 7.305e-05 | 0.0009016 |
378 | NEGATIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 9 | 541 | 7.683e-05 | 0.0009432 |
379 | NEGATIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 9 | 541 | 7.683e-05 | 0.0009432 |
380 | CELLULAR EXTRAVASATION | 3 | 25 | 7.84e-05 | 0.0009549 |
381 | APOPTOTIC NUCLEAR CHANGES | 3 | 25 | 7.84e-05 | 0.0009549 |
382 | EPITHELIAL CELL APOPTOTIC PROCESS | 3 | 25 | 7.84e-05 | 0.0009549 |
383 | NEGATIVE REGULATION OF NF KAPPAB TRANSCRIPTION FACTOR ACTIVITY | 4 | 68 | 7.972e-05 | 0.0009685 |
384 | B CELL ACTIVATION | 5 | 132 | 8.075e-05 | 0.0009784 |
385 | PROTEIN COMPLEX BIOGENESIS | 13 | 1132 | 8.314e-05 | 0.001002 |
386 | PROTEIN COMPLEX ASSEMBLY | 13 | 1132 | 8.314e-05 | 0.001002 |
387 | REGULATION OF HEMOPOIESIS | 7 | 314 | 8.537e-05 | 0.001026 |
388 | DEVELOPMENTAL PROGRAMMED CELL DEATH | 3 | 26 | 8.841e-05 | 0.001058 |
389 | NEGATIVE REGULATION OF LIPID TRANSPORT | 3 | 26 | 8.841e-05 | 0.001058 |
390 | POSITIVE REGULATION OF TYPE I INTERFERON PRODUCTION | 4 | 70 | 8.93e-05 | 0.001065 |
391 | POSITIVE REGULATION OF DEVELOPMENTAL PROCESS | 13 | 1142 | 9.087e-05 | 0.001081 |
392 | NEGATIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 12 | 983 | 9.132e-05 | 0.001084 |
393 | EMBRYO DEVELOPMENT ENDING IN BIRTH OR EGG HATCHING | 9 | 554 | 9.207e-05 | 0.00109 |
394 | REGULATION OF FATTY ACID TRANSPORT | 3 | 27 | 9.922e-05 | 0.001172 |
395 | REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE SIGNALING | 5 | 138 | 9.963e-05 | 0.001174 |
396 | POSITIVE REGULATION OF ACUTE INFLAMMATORY RESPONSE | 3 | 28 | 0.0001109 | 0.001299 |
397 | MODULATION BY SYMBIONT OF HOST CELLULAR PROCESS | 3 | 28 | 0.0001109 | 0.001299 |
398 | NEGATIVE REGULATION OF PROTEOLYSIS | 7 | 329 | 0.0001141 | 0.001334 |
399 | POSITIVE REGULATION OF CARBOHYDRATE METABOLIC PROCESS | 4 | 75 | 0.0001169 | 0.00136 |
400 | GRANULOCYTE MIGRATION | 4 | 75 | 0.0001169 | 0.00136 |
401 | PROTEIN IMPORT INTO NUCLEUS TRANSLOCATION | 3 | 29 | 0.0001234 | 0.001424 |
402 | MUSCLE ADAPTATION | 3 | 29 | 0.0001234 | 0.001424 |
403 | POSITIVE REGULATION OF MONOOXYGENASE ACTIVITY | 3 | 29 | 0.0001234 | 0.001424 |
404 | RESPONSE TO IONIZING RADIATION | 5 | 145 | 0.0001258 | 0.001447 |
405 | ORGANOPHOSPHATE BIOSYNTHETIC PROCESS | 8 | 450 | 0.0001259 | 0.001447 |
406 | REGULATION OF LEUKOCYTE DIFFERENTIATION | 6 | 232 | 0.0001263 | 0.001447 |
407 | RESPONSE TO ENDOPLASMIC RETICULUM STRESS | 6 | 233 | 0.0001293 | 0.001478 |
408 | CELLULAR RESPONSE TO INSULIN STIMULUS | 5 | 146 | 0.0001299 | 0.001481 |
409 | LYMPHOCYTE COSTIMULATION | 4 | 78 | 0.0001362 | 0.001549 |
410 | NEGATIVE REGULATION OF B CELL ACTIVATION | 3 | 30 | 0.0001367 | 0.001552 |
411 | RESPONSE TO TRANSITION METAL NANOPARTICLE | 5 | 148 | 0.0001385 | 0.001567 |
412 | NEGATIVE REGULATION OF TRANSPORT | 8 | 458 | 0.0001421 | 0.001601 |
413 | MUSCLE CELL DIFFERENTIATION | 6 | 237 | 0.0001418 | 0.001601 |
414 | SEXUAL REPRODUCTION | 10 | 730 | 0.0001491 | 0.001676 |
415 | POSITIVE REGULATION OF INTERLEUKIN 2 PRODUCTION | 3 | 31 | 0.000151 | 0.001693 |
416 | MITOCHONDRION ORGANIZATION | 9 | 594 | 0.0001559 | 0.001743 |
417 | REGULATION OF REACTIVE OXYGEN SPECIES METABOLIC PROCESS | 5 | 152 | 0.0001569 | 0.00175 |
418 | REGULATION OF PROTEIN MATURATION | 4 | 82 | 0.0001653 | 0.00184 |
419 | NEGATIVE REGULATION OF TRANSFERASE ACTIVITY | 7 | 351 | 0.0001701 | 0.001885 |
420 | NEGATIVE REGULATION OF PEPTIDASE ACTIVITY | 6 | 245 | 0.0001699 | 0.001885 |
421 | PROTEIN IMPORT | 5 | 155 | 0.0001719 | 0.001899 |
422 | DEVELOPMENTAL PROCESS INVOLVED IN REPRODUCTION | 9 | 602 | 0.0001723 | 0.001899 |
423 | RESPONSE TO FATTY ACID | 4 | 83 | 0.0001732 | 0.001905 |
424 | CELLULAR RESPONSE TO INORGANIC SUBSTANCE | 5 | 156 | 0.0001771 | 0.001939 |
425 | PROTEIN LOCALIZATION TO NUCLEUS | 5 | 156 | 0.0001771 | 0.001939 |
426 | NEGATIVE REGULATION OF ANION TRANSPORT | 3 | 33 | 0.0001824 | 0.001988 |
427 | HEXOSE METABOLIC PROCESS | 5 | 157 | 0.0001825 | 0.001988 |
428 | REGULATION OF JNK CASCADE | 5 | 159 | 0.0001935 | 0.002104 |
429 | POSITIVE REGULATION OF REACTIVE OXYGEN SPECIES METABOLIC PROCESS | 4 | 86 | 0.0001987 | 0.002155 |
430 | NEGATIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 9 | 616 | 0.0002045 | 0.002213 |
431 | CELLULAR LIPID METABOLIC PROCESS | 11 | 913 | 0.0002083 | 0.002249 |
432 | SYSTEM PROCESS | 16 | 1785 | 0.0002105 | 0.002267 |
433 | REGULATION OF PEPTIDE TRANSPORT | 6 | 256 | 0.0002154 | 0.002315 |
434 | REGULATION OF GENERATION OF PRECURSOR METABOLITES AND ENERGY | 4 | 89 | 0.0002267 | 0.002425 |
435 | EPITHELIAL CELL PROLIFERATION | 4 | 89 | 0.0002267 | 0.002425 |
436 | REGULATION OF OXIDOREDUCTASE ACTIVITY | 4 | 90 | 0.0002367 | 0.00252 |
437 | CALCIUM MEDIATED SIGNALING | 4 | 90 | 0.0002367 | 0.00252 |
438 | POSITIVE REGULATION OF MITOCHONDRION ORGANIZATION | 5 | 167 | 0.0002431 | 0.002582 |
439 | TRANSMEMBRANE RECEPTOR PROTEIN TYROSINE KINASE SIGNALING PATHWAY | 8 | 498 | 0.0002511 | 0.002662 |
440 | MODULATION BY VIRUS OF HOST MORPHOLOGY OR PHYSIOLOGY | 3 | 37 | 0.0002573 | 0.002721 |
441 | WNT SIGNALING PATHWAY CALCIUM MODULATING PATHWAY | 3 | 39 | 0.0003012 | 0.003169 |
442 | ERBB2 SIGNALING PATHWAY | 3 | 39 | 0.0003012 | 0.003169 |
443 | HOMEOSTASIS OF NUMBER OF CELLS | 5 | 175 | 0.0003017 | 0.003169 |
444 | MYELOID LEUKOCYTE DIFFERENTIATION | 4 | 96 | 0.0003031 | 0.003169 |
445 | FEMALE GAMETE GENERATION | 4 | 96 | 0.0003031 | 0.003169 |
446 | NEGATIVE REGULATION OF DEVELOPMENTAL PROCESS | 10 | 801 | 0.0003146 | 0.003275 |
447 | CELLULAR COMPONENT DISASSEMBLY | 8 | 515 | 0.0003147 | 0.003275 |
448 | MITOCHONDRIAL TRANSPORT | 5 | 177 | 0.0003179 | 0.003296 |
449 | REGULATION OF PROTEIN SECRETION | 7 | 389 | 0.0003181 | 0.003296 |
450 | REPRODUCTION | 13 | 1297 | 0.00032 | 0.003309 |
451 | REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 3 | 40 | 0.0003249 | 0.003344 |
452 | REGULATION OF MEIOTIC CELL CYCLE | 3 | 40 | 0.0003249 | 0.003344 |
453 | REGULATION OF PROTEIN CATABOLIC PROCESS | 7 | 393 | 0.0003383 | 0.003475 |
454 | MYELOID LEUKOCYTE MIGRATION | 4 | 99 | 0.0003409 | 0.003494 |
455 | INTERSPECIES INTERACTION BETWEEN ORGANISMS | 9 | 662 | 0.0003477 | 0.003545 |
456 | SYMBIOSIS ENCOMPASSING MUTUALISM THROUGH PARASITISM | 9 | 662 | 0.0003477 | 0.003545 |
457 | RESPONSE TO LIGHT STIMULUS | 6 | 280 | 0.0003482 | 0.003545 |
458 | REGULATION OF LIPID STORAGE | 3 | 41 | 0.0003497 | 0.003553 |
459 | ESTABLISHMENT OF LOCALIZATION IN CELL | 15 | 1676 | 0.0003525 | 0.003573 |
460 | MUSCLE SYSTEM PROCESS | 6 | 282 | 0.0003616 | 0.003658 |
461 | REGULATION OF MYELOID CELL DIFFERENTIATION | 5 | 183 | 0.0003706 | 0.00374 |
462 | CELLULAR RESPONSE TO OXIDATIVE STRESS | 5 | 184 | 0.0003799 | 0.003826 |
463 | POSITIVE REGULATION OF CELL DIFFERENTIATION | 10 | 823 | 0.0003899 | 0.003918 |
464 | MYELOID LEUKOCYTE MEDIATED IMMUNITY | 3 | 43 | 0.0004029 | 0.004032 |
465 | REGULATION OF POLYSACCHARIDE METABOLIC PROCESS | 3 | 43 | 0.0004029 | 0.004032 |
466 | REGULATION OF INTERLEUKIN 6 PRODUCTION | 4 | 104 | 0.0004112 | 0.004097 |
467 | CELLULAR RESPONSE TO REACTIVE OXYGEN SPECIES | 4 | 104 | 0.0004112 | 0.004097 |
468 | LIPID BIOSYNTHETIC PROCESS | 8 | 539 | 0.0004263 | 0.004229 |
469 | TISSUE DEVELOPMENT | 14 | 1518 | 0.0004259 | 0.004229 |
470 | REGULATION OF CELL DEVELOPMENT | 10 | 836 | 0.000441 | 0.004366 |
471 | PROTEIN COMPLEX SUBUNIT ORGANIZATION | 14 | 1527 | 0.0004521 | 0.004466 |
472 | MODIFICATION BY SYMBIONT OF HOST MORPHOLOGY OR PHYSIOLOGY | 3 | 45 | 0.0004611 | 0.004536 |
473 | REGULATION OF ALCOHOL BIOSYNTHETIC PROCESS | 3 | 45 | 0.0004611 | 0.004536 |
474 | ENZYME LINKED RECEPTOR PROTEIN SIGNALING PATHWAY | 9 | 689 | 0.000465 | 0.004565 |
475 | PEPTIDYL THREONINE MODIFICATION | 3 | 46 | 0.0004921 | 0.00482 |
476 | POSITIVE REGULATION OF LOCOMOTION | 7 | 420 | 0.0005035 | 0.004922 |
477 | REGULATION OF STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE | 5 | 197 | 0.0005188 | 0.00505 |
478 | NEGATIVE REGULATION OF PHOSPHORYLATION | 7 | 422 | 0.0005179 | 0.00505 |
479 | POSITIVE REGULATION OF OXIDOREDUCTASE ACTIVITY | 3 | 47 | 0.0005244 | 0.005094 |
480 | REGULATION OF TYPE I INTERFERON PRODUCTION | 4 | 111 | 0.0005263 | 0.005102 |
481 | REGULATION OF CELL CYCLE PROCESS | 8 | 558 | 0.0005359 | 0.005184 |
482 | REGULATION OF LIPID KINASE ACTIVITY | 3 | 48 | 0.000558 | 0.005353 |
483 | REGULATION OF NF KAPPAB IMPORT INTO NUCLEUS | 3 | 48 | 0.000558 | 0.005353 |
484 | REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION TO PLASMA MEMBRANE | 3 | 48 | 0.000558 | 0.005353 |
485 | REGULATION OF INTERLEUKIN 2 PRODUCTION | 3 | 48 | 0.000558 | 0.005353 |
486 | POSITIVE REGULATION OF INFLAMMATORY RESPONSE | 4 | 113 | 0.000563 | 0.005379 |
487 | PROTEIN HETEROOLIGOMERIZATION | 4 | 113 | 0.000563 | 0.005379 |
488 | REGULATION OF LYMPHOCYTE MEDIATED IMMUNITY | 4 | 114 | 0.000582 | 0.005538 |
489 | MONOSACCHARIDE METABOLIC PROCESS | 5 | 202 | 0.0005813 | 0.005538 |
490 | PLASMA MEMBRANE ORGANIZATION | 5 | 203 | 0.0005945 | 0.005594 |
491 | REGULATION OF CERAMIDE BIOSYNTHETIC PROCESS | 2 | 11 | 0.0005963 | 0.005594 |
492 | POSITIVE REGULATION OF HAIR CYCLE | 2 | 11 | 0.0005963 | 0.005594 |
493 | REGULATION OF FEVER GENERATION | 2 | 11 | 0.0005963 | 0.005594 |
494 | REGULATION OF STEROID BIOSYNTHETIC PROCESS | 3 | 49 | 0.0005929 | 0.005594 |
495 | REGULATION OF NECROPTOTIC PROCESS | 2 | 11 | 0.0005963 | 0.005594 |
496 | BIOLOGICAL ADHESION | 11 | 1032 | 0.0005903 | 0.005594 |
497 | NEGATIVE REGULATION OF CELL CYCLE | 7 | 433 | 0.0006033 | 0.005648 |
498 | PROTEIN OLIGOMERIZATION | 7 | 434 | 0.0006115 | 0.005714 |
499 | REGULATION OF ORGANIC ACID TRANSPORT | 3 | 50 | 0.0006293 | 0.005868 |
500 | REGULATION OF LEUKOCYTE PROLIFERATION | 5 | 206 | 0.0006353 | 0.005912 |
501 | MACROMOLECULAR COMPLEX ASSEMBLY | 13 | 1398 | 0.0006542 | 0.006076 |
502 | REGULATION OF INTERLEUKIN 12 PRODUCTION | 3 | 51 | 0.000667 | 0.006183 |
503 | RESPONSE TO EXTRACELLULAR STIMULUS | 7 | 441 | 0.0006721 | 0.006217 |
504 | NEGATIVE REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION | 5 | 209 | 0.0006781 | 0.006236 |
505 | REGULATION OF PEPTIDE SECRETION | 5 | 209 | 0.0006781 | 0.006236 |
506 | GERM CELL DEVELOPMENT | 5 | 209 | 0.0006781 | 0.006236 |
507 | CYTOKINE PRODUCTION | 4 | 120 | 0.0007058 | 0.006455 |
508 | REGULATION OF T CELL MEDIATED IMMUNITY | 3 | 52 | 0.0007062 | 0.006455 |
509 | POSITIVE REGULATION OF INTRINSIC APOPTOTIC SIGNALING PATHWAY | 3 | 52 | 0.0007062 | 0.006455 |
510 | POSITIVE REGULATION OF PROTEIN SECRETION | 5 | 211 | 0.0007079 | 0.006459 |
511 | REGULATION OF CHEMOKINE BIOSYNTHETIC PROCESS | 2 | 12 | 0.000714 | 0.006464 |
512 | I KAPPAB PHOSPHORYLATION | 2 | 12 | 0.000714 | 0.006464 |
513 | MYELIN MAINTENANCE | 2 | 12 | 0.000714 | 0.006464 |
514 | POSITIVE REGULATION OF INTERLEUKIN 2 BIOSYNTHETIC PROCESS | 2 | 12 | 0.000714 | 0.006464 |
515 | MULTI ORGANISM REPRODUCTIVE PROCESS | 10 | 891 | 0.0007238 | 0.006539 |
516 | REGULATION OF HOMEOSTATIC PROCESS | 7 | 447 | 0.0007277 | 0.006562 |
517 | NEGATIVE REGULATION OF AUTOPHAGY | 3 | 53 | 0.0007468 | 0.006708 |
518 | POSITIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY | 3 | 53 | 0.0007468 | 0.006708 |
519 | REGULATION OF ADAPTIVE IMMUNE RESPONSE | 4 | 123 | 0.0007742 | 0.006924 |
520 | MEMBRANE ORGANIZATION | 10 | 899 | 0.0007753 | 0.006924 |
521 | T CELL DIFFERENTIATION | 4 | 123 | 0.0007742 | 0.006924 |
522 | NEGATIVE REGULATION OF REPRODUCTIVE PROCESS | 3 | 54 | 0.0007888 | 0.007004 |
523 | POSITIVE REGULATION OF HOMEOSTATIC PROCESS | 5 | 216 | 0.0007866 | 0.007004 |
524 | REGULATION OF MITOCHONDRIAL MEMBRANE POTENTIAL | 3 | 54 | 0.0007888 | 0.007004 |
525 | REGULATION OF B CELL PROLIFERATION | 3 | 55 | 0.0008323 | 0.007377 |
526 | REGULATION OF SPHINGOLIPID BIOSYNTHETIC PROCESS | 2 | 13 | 0.000842 | 0.007392 |
527 | REGULATION OF MEMBRANE LIPID METABOLIC PROCESS | 2 | 13 | 0.000842 | 0.007392 |
528 | POSITIVE REGULATION OF STEROID BIOSYNTHETIC PROCESS | 2 | 13 | 0.000842 | 0.007392 |
529 | REGULATION OF HISTONE PHOSPHORYLATION | 2 | 13 | 0.000842 | 0.007392 |
530 | PROTEIN AUTOPROCESSING | 2 | 13 | 0.000842 | 0.007392 |
531 | REGULATION OF NERVOUS SYSTEM DEVELOPMENT | 9 | 750 | 0.000853 | 0.007475 |
532 | NEGATIVE REGULATION OF ION TRANSPORT | 4 | 127 | 0.0008725 | 0.007631 |
533 | REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION TO MITOCHONDRION | 4 | 128 | 0.0008984 | 0.007843 |
534 | REGULATION OF CYTOKINE PRODUCTION INVOLVED IN IMMUNE RESPONSE | 3 | 57 | 0.0009239 | 0.00805 |
535 | REGULATION OF DNA METABOLIC PROCESS | 6 | 340 | 0.0009638 | 0.008383 |
536 | MACROMOLECULE CATABOLIC PROCESS | 10 | 926 | 0.000972 | 0.008438 |
537 | POSITIVE REGULATION OF LEUKOCYTE DIFFERENTIATION | 4 | 131 | 0.0009793 | 0.008446 |
538 | REGULATION OF FIBROBLAST APOPTOTIC PROCESS | 2 | 14 | 0.0009802 | 0.008446 |
539 | INSULIN LIKE GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 2 | 14 | 0.0009802 | 0.008446 |
540 | T CELL MIGRATION | 2 | 14 | 0.0009802 | 0.008446 |
541 | POSITIVE REGULATION OF SMOOTH MUSCLE CELL PROLIFERATION | 3 | 60 | 0.001073 | 0.009226 |
542 | NEGATIVE REGULATION OF NEURON APOPTOTIC PROCESS | 4 | 135 | 0.001095 | 0.009383 |
543 | POSITIVE REGULATION OF STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE | 4 | 135 | 0.001095 | 0.009383 |
544 | NEGATIVE REGULATION OF PHOSPHOPROTEIN PHOSPHATASE ACTIVITY | 2 | 15 | 0.001129 | 0.009428 |
545 | REGULATION OF HEAT GENERATION | 2 | 15 | 0.001129 | 0.009428 |
546 | RESPONSE TO MURAMYL DIPEPTIDE | 2 | 15 | 0.001129 | 0.009428 |
547 | REGULATION OF PHOSPHOLIPID METABOLIC PROCESS | 3 | 61 | 0.001126 | 0.009428 |
548 | NEGATIVE REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY | 4 | 136 | 0.001125 | 0.009428 |
549 | REGULATION OF HAIR FOLLICLE DEVELOPMENT | 2 | 15 | 0.001129 | 0.009428 |
550 | CELLULAR RESPONSE TO NITRIC OXIDE | 2 | 15 | 0.001129 | 0.009428 |
551 | CELLULAR RESPONSE TO HYDROGEN PEROXIDE | 3 | 61 | 0.001126 | 0.009428 |
552 | RESPIRATORY BURST | 2 | 15 | 0.001129 | 0.009428 |
553 | NEGATIVE REGULATION OF INTERLEUKIN 12 PRODUCTION | 2 | 15 | 0.001129 | 0.009428 |
554 | NEGATIVE REGULATION OF B CELL PROLIFERATION | 2 | 15 | 0.001129 | 0.009428 |
555 | CHRONIC INFLAMMATORY RESPONSE | 2 | 15 | 0.001129 | 0.009428 |
556 | POSITIVE REGULATION OF MEMBRANE PROTEIN ECTODOMAIN PROTEOLYSIS | 2 | 15 | 0.001129 | 0.009428 |
557 | NEUROTROPHIN TRK RECEPTOR SIGNALING PATHWAY | 2 | 15 | 0.001129 | 0.009428 |
558 | EPITHELIUM DEVELOPMENT | 10 | 945 | 0.001134 | 0.009454 |
559 | CELLULAR RESPONSE TO RADIATION | 4 | 137 | 0.001156 | 0.009625 |
560 | MAINTENANCE OF LOCATION | 4 | 138 | 0.001188 | 0.00987 |
561 | NEGATIVE REGULATION OF GENE EXPRESSION | 13 | 1493 | 0.001203 | 0.009972 |
562 | CARDIOVASCULAR SYSTEM DEVELOPMENT | 9 | 788 | 0.001207 | 0.009972 |
563 | CIRCULATORY SYSTEM DEVELOPMENT | 9 | 788 | 0.001207 | 0.009972 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY BINDING | 10 | 47 | 4.143e-16 | 3.849e-13 |
2 | CYTOKINE RECEPTOR BINDING | 15 | 271 | 1.191e-14 | 5.533e-12 |
3 | KINASE ACTIVITY | 22 | 842 | 1.863e-14 | 5.77e-12 |
4 | ENZYME BINDING | 28 | 1737 | 3.224e-13 | 7.487e-11 |
5 | TRANSFERASE ACTIVITY TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 22 | 992 | 5.114e-13 | 9.502e-11 |
6 | PROTEIN SERINE THREONINE KINASE ACTIVITY | 16 | 445 | 1.097e-12 | 1.699e-10 |
7 | CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC PROCESS | 6 | 15 | 5.492e-12 | 7.289e-10 |
8 | DEATH RECEPTOR BINDING | 6 | 18 | 2.021e-11 | 2.347e-09 |
9 | PROTEIN KINASE ACTIVITY | 17 | 640 | 2.383e-11 | 2.459e-09 |
10 | UBIQUITIN LIKE PROTEIN LIGASE BINDING | 12 | 264 | 6.865e-11 | 6.378e-09 |
11 | PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 8 | 70 | 8.251e-11 | 6.969e-09 |
12 | X1 PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 7 | 43 | 1.005e-10 | 7.779e-09 |
13 | PHOSPHATIDYLINOSITOL KINASE ACTIVITY | 7 | 51 | 3.535e-10 | 2.526e-08 |
14 | PROTEIN HETERODIMERIZATION ACTIVITY | 14 | 468 | 3.835e-10 | 2.545e-08 |
15 | CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 8 | 86 | 4.447e-10 | 2.754e-08 |
16 | TUMOR NECROSIS FACTOR RECEPTOR BINDING | 6 | 30 | 6.265e-10 | 3.638e-08 |
17 | KINASE BINDING | 15 | 606 | 1.13e-09 | 6.175e-08 |
18 | ADENYL NUCLEOTIDE BINDING | 22 | 1514 | 1.85e-09 | 9.548e-08 |
19 | IDENTICAL PROTEIN BINDING | 18 | 1209 | 5.649e-08 | 2.762e-06 |
20 | RIBONUCLEOTIDE BINDING | 22 | 1860 | 7.891e-08 | 3.491e-06 |
21 | ENZYME REGULATOR ACTIVITY | 16 | 959 | 7.733e-08 | 3.491e-06 |
22 | PROTEIN DIMERIZATION ACTIVITY | 17 | 1149 | 1.575e-07 | 6.653e-06 |
23 | CYSTEINE TYPE PEPTIDASE ACTIVITY | 8 | 184 | 1.809e-07 | 7.256e-06 |
24 | KINASE REGULATOR ACTIVITY | 8 | 186 | 1.965e-07 | 7.256e-06 |
25 | INTERLEUKIN 1 RECEPTOR BINDING | 4 | 16 | 2.031e-07 | 7.256e-06 |
26 | PHOSPHATIDYLINOSITOL PHOSPHATE KINASE ACTIVITY | 4 | 16 | 2.031e-07 | 7.256e-06 |
27 | CYSTEINE TYPE ENDOPEPTIDASE REGULATOR ACTIVITY INVOLVED IN APOPTOTIC PROCESS | 5 | 42 | 2.801e-07 | 9.638e-06 |
28 | MOLECULAR FUNCTION REGULATOR | 18 | 1353 | 3.051e-07 | 1.012e-05 |
29 | PROTEIN DOMAIN SPECIFIC BINDING | 12 | 624 | 9.567e-07 | 3.065e-05 |
30 | RECEPTOR BINDING | 18 | 1476 | 1.09e-06 | 3.374e-05 |
31 | DEATH RECEPTOR ACTIVITY | 4 | 24 | 1.162e-06 | 3.482e-05 |
32 | PROTEASE BINDING | 6 | 104 | 1.319e-06 | 3.83e-05 |
33 | PROTEIN SERINE THREONINE KINASE INHIBITOR ACTIVITY | 4 | 30 | 2.952e-06 | 8.31e-05 |
34 | PROTEIN PHOSPHATASE BINDING | 6 | 120 | 3.045e-06 | 8.321e-05 |
35 | INSULIN RECEPTOR SUBSTRATE BINDING | 3 | 11 | 5.816e-06 | 0.0001544 |
36 | PROTEIN KINASE A BINDING | 4 | 42 | 1.17e-05 | 0.0003018 |
37 | PROTEIN KINASE A CATALYTIC SUBUNIT BINDING | 3 | 15 | 1.589e-05 | 0.0003989 |
38 | PHOSPHATASE BINDING | 6 | 162 | 1.708e-05 | 0.0004175 |
39 | SIGNAL TRANSDUCER ACTIVITY | 17 | 1731 | 4.057e-05 | 0.0009665 |
40 | PEPTIDASE ACTIVATOR ACTIVITY INVOLVED IN APOPTOTIC PROCESS | 3 | 21 | 4.577e-05 | 0.001063 |
41 | PROTEIN COMPLEX BINDING | 12 | 935 | 5.657e-05 | 0.001282 |
42 | CAMP BINDING | 3 | 23 | 6.066e-05 | 0.001342 |
43 | GROWTH FACTOR RECEPTOR BINDING | 5 | 129 | 7.241e-05 | 0.001564 |
44 | PEPTIDASE REGULATOR ACTIVITY | 6 | 214 | 8.106e-05 | 0.001712 |
45 | ENDOPEPTIDASE ACTIVITY | 8 | 448 | 0.0001221 | 0.002521 |
46 | PROTEIN HOMODIMERIZATION ACTIVITY | 10 | 722 | 0.0001363 | 0.002753 |
47 | HEAT SHOCK PROTEIN BINDING | 4 | 89 | 0.0002267 | 0.004388 |
48 | KINASE INHIBITOR ACTIVITY | 4 | 89 | 0.0002267 | 0.004388 |
49 | CYCLIC NUCLEOTIDE BINDING | 3 | 36 | 0.000237 | 0.004494 |
50 | ENZYME INHIBITOR ACTIVITY | 7 | 378 | 0.0002674 | 0.004968 |
51 | PEPTIDASE ACTIVATOR ACTIVITY | 3 | 38 | 0.0002787 | 0.005077 |
52 | SCAFFOLD PROTEIN BINDING | 3 | 45 | 0.0004611 | 0.008237 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | TRANSFERASE COMPLEX TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 15 | 237 | 1.637e-15 | 4.779e-13 |
2 | MEMBRANE MICRODOMAIN | 16 | 288 | 1.31e-15 | 4.779e-13 |
3 | PHOSPHATIDYLINOSITOL 3 KINASE COMPLEX | 7 | 20 | 2.568e-13 | 4.999e-11 |
4 | CATALYTIC COMPLEX | 22 | 1038 | 1.263e-12 | 1.844e-10 |
5 | MEMBRANE PROTEIN COMPLEX | 20 | 1020 | 6.952e-11 | 8.12e-09 |
6 | PROTEIN KINASE COMPLEX | 8 | 90 | 6.428e-10 | 6.257e-08 |
7 | TRANSFERASE COMPLEX | 16 | 703 | 9.69e-10 | 8.084e-08 |
8 | CILIARY BASE | 5 | 23 | 1.164e-08 | 8.496e-07 |
9 | MEMBRANE REGION | 17 | 1134 | 1.306e-07 | 8.472e-06 |
10 | CYTOSOLIC PART | 8 | 223 | 7.807e-07 | 4.56e-05 |
11 | PLASMA MEMBRANE PROTEIN COMPLEX | 11 | 510 | 9.417e-07 | 4.999e-05 |
12 | CD40 RECEPTOR COMPLEX | 3 | 11 | 5.816e-06 | 0.0002613 |
13 | IKAPPAB KINASE COMPLEX | 3 | 11 | 5.816e-06 | 0.0002613 |
14 | EXTRINSIC COMPONENT OF MEMBRANE | 7 | 252 | 2.119e-05 | 0.0008839 |
15 | RECEPTOR COMPLEX | 7 | 327 | 0.0001099 | 0.004278 |
16 | VACUOLE | 13 | 1180 | 0.0001263 | 0.004608 |
17 | PLASMA MEMBRANE RAFT | 4 | 86 | 0.0001987 | 0.006825 |
18 | MITOCHONDRION | 15 | 1633 | 0.0002663 | 0.00864 |
19 | PLASMA MEMBRANE RECEPTOR COMPLEX | 5 | 175 | 0.0003017 | 0.009274 |
Num | Pathway | Pathview | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|---|
1 | hsa04210_Apoptosis | 67 | 89 | 1.112e-173 | 1.968e-171 | |
2 | hsa04380_Osteoclast_differentiation | 25 | 128 | 1.6e-38 | 1.416e-36 | |
3 | hsa04620_Toll.like_receptor_signaling_pathway | 22 | 102 | 7.394e-35 | 4.362e-33 | |
4 | hsa04660_T_cell_receptor_signaling_pathway | 22 | 108 | 2.97e-34 | 1.314e-32 | |
5 | hsa04662_B_cell_receptor_signaling_pathway | 20 | 75 | 9.638e-34 | 3.412e-32 | |
6 | hsa04722_Neurotrophin_signaling_pathway | 22 | 127 | 1.452e-32 | 4.285e-31 | |
7 | hsa04010_MAPK_signaling_pathway | 26 | 268 | 9.781e-32 | 2.473e-30 | |
8 | hsa04370_VEGF_signaling_pathway | 16 | 76 | 3.383e-25 | 7.485e-24 | |
9 | hsa04650_Natural_killer_cell_mediated_cytotoxicity | 18 | 136 | 2.136e-24 | 4.2e-23 | |
10 | hsa04910_Insulin_signaling_pathway | 18 | 138 | 2.814e-24 | 4.981e-23 | |
11 | hsa04062_Chemokine_signaling_pathway | 19 | 189 | 2.209e-23 | 3.554e-22 | |
12 | hsa04920_Adipocytokine_signaling_pathway | 13 | 68 | 5.289e-20 | 7.801e-19 | |
13 | hsa04914_Progesterone.mediated_oocyte_maturation | 13 | 87 | 1.645e-18 | 2.239e-17 | |
14 | hsa04621_NOD.like_receptor_signaling_pathway | 11 | 59 | 6.212e-17 | 7.854e-16 | |
15 | hsa04510_Focal_adhesion | 15 | 200 | 1.29e-16 | 1.522e-15 | |
16 | hsa04973_Carbohydrate_digestion_and_absorption | 10 | 44 | 2.001e-16 | 2.213e-15 | |
17 | hsa04622_RIG.I.like_receptor_signaling_pathway | 11 | 71 | 5.511e-16 | 5.738e-15 | |
18 | hsa04150_mTOR_signaling_pathway | 10 | 52 | 1.249e-15 | 1.229e-14 | |
19 | hsa04664_Fc_epsilon_RI_signaling_pathway | 11 | 79 | 1.905e-15 | 1.775e-14 | |
20 | hsa04012_ErbB_signaling_pathway | 11 | 87 | 5.784e-15 | 5.119e-14 | |
21 | hsa04630_Jak.STAT_signaling_pathway | 12 | 155 | 1.268e-13 | 1.068e-12 | |
22 | hsa04666_Fc_gamma_R.mediated_phagocytosis | 10 | 95 | 7.137e-13 | 5.742e-12 | |
23 | hsa04960_Aldosterone.regulated_sodium_reabsorption | 7 | 42 | 8.435e-11 | 6.491e-10 | |
24 | hsa04623_Cytosolic_DNA.sensing_pathway | 7 | 56 | 6.989e-10 | 5.154e-09 | |
25 | hsa04115_p53_signaling_pathway | 7 | 69 | 3.142e-09 | 2.224e-08 | |
26 | hsa04720_Long.term_potentiation | 7 | 70 | 3.482e-09 | 2.37e-08 | |
27 | hsa04070_Phosphatidylinositol_signaling_system | 7 | 78 | 7.514e-09 | 4.926e-08 | |
28 | hsa04114_Oocyte_meiosis | 7 | 114 | 1.065e-07 | 6.729e-07 | |
29 | hsa04670_Leukocyte_transendothelial_migration | 7 | 117 | 1.273e-07 | 7.77e-07 | |
30 | hsa04310_Wnt_signaling_pathway | 7 | 151 | 7.239e-07 | 4.271e-06 | |
31 | hsa04020_Calcium_signaling_pathway | 7 | 177 | 2.099e-06 | 1.199e-05 | |
32 | hsa04810_Regulation_of_actin_cytoskeleton | 7 | 214 | 7.346e-06 | 4.063e-05 | |
33 | hsa00562_Inositol_phosphate_metabolism | 4 | 57 | 3.975e-05 | 0.0002132 | |
34 | hsa04640_Hematopoietic_cell_lineage | 4 | 88 | 0.0002171 | 0.00113 | |
35 | hsa04962_Vasopressin.regulated_water_reabsorption | 3 | 44 | 0.0004314 | 0.002181 | |
36 | hsa04742_Taste_transduction | 3 | 52 | 0.0007062 | 0.003472 | |
37 | hsa04340_Hedgehog_signaling_pathway | 3 | 56 | 0.0008773 | 0.004197 | |
38 | hsa04360_Axon_guidance | 4 | 130 | 0.0009518 | 0.004433 | |
39 | hsa04976_Bile_secretion | 3 | 71 | 0.001745 | 0.007921 | |
40 | hsa04971_Gastric_acid_secretion | 3 | 74 | 0.001965 | 0.008697 | |
41 | hsa04141_Protein_processing_in_endoplasmic_reticulum | 4 | 168 | 0.00244 | 0.01053 | |
42 | hsa04970_Salivary_secretion | 3 | 89 | 0.003322 | 0.014 | |
43 | hsa04540_Gap_junction | 3 | 90 | 0.003429 | 0.01411 | |
44 | hsa04912_GnRH_signaling_pathway | 3 | 101 | 0.004739 | 0.01864 | |
45 | hsa04916_Melanogenesis | 3 | 101 | 0.004739 | 0.01864 | |
46 | hsa04270_Vascular_smooth_muscle_contraction | 3 | 116 | 0.006955 | 0.02676 | |
47 | hsa04530_Tight_junction | 3 | 133 | 0.0101 | 0.03805 | |
48 | hsa04120_Ubiquitin_mediated_proteolysis | 2 | 139 | 0.07916 | 0.2919 | |
49 | hsa04740_Olfactory_transduction | 3 | 388 | 0.141 | 0.5092 |
Num | lncRNA | miRNAs | miRNAs count | Gene | Sponge regulatory network | lncRNA log2FC | lncRNA pvalue | Gene log2FC | Gene pvalue | lncRNA-gene Pearson correlation |
---|---|---|---|---|---|---|---|---|---|---|
1 | RP11-4O1.2 | hsa-miR-155-5p;hsa-miR-23a-3p;hsa-miR-23b-3p;hsa-miR-27a-3p;hsa-miR-27b-3p;hsa-miR-33a-3p;hsa-miR-374b-5p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-708-3p | 10 | APAF1 | Sponge network | 0.371 | 0.46439 | 0.352 | 0.33131 | 0.476 |
2 | MAGI2-AS3 |
hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-142-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-20b-5p;hsa-miR-3065-5p;hsa-miR-362-3p;hsa-miR-93-5p | 11 | AKT3 | Sponge network | -4.563 | 0 | -3.327 | 1.0E-5 | 0.454 |
3 | RP11-389C8.2 |
hsa-let-7a-3p;hsa-let-7f-1-3p;hsa-miR-141-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-18a-5p;hsa-miR-193a-3p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-200a-3p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-2110;hsa-miR-3065-5p;hsa-miR-429;hsa-miR-93-5p | 18 | PRKACB | Sponge network | -3.089 | 2.0E-5 | -1.469 | 0.00691 | 0.394 |
4 | MIR143HG |
hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-142-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-20b-5p;hsa-miR-3065-5p;hsa-miR-93-5p | 10 | AKT3 | Sponge network | -6.51 | 0 | -3.327 | 1.0E-5 | 0.394 |
5 | RP11-284N8.3 |
hsa-miR-141-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-18a-5p;hsa-miR-19b-3p;hsa-miR-200a-3p;hsa-miR-200b-3p;hsa-miR-3065-5p;hsa-miR-590-5p;hsa-miR-93-5p;hsa-miR-96-5p | 13 | PRKACB | Sponge network | -0.845 | 0.52848 | -1.469 | 0.00691 | 0.371 |
6 | RP11-389C8.2 |
hsa-miR-15b-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-192-5p;hsa-miR-200a-5p;hsa-miR-200b-3p;hsa-miR-200b-5p;hsa-miR-200c-3p;hsa-miR-20a-3p;hsa-miR-215-5p;hsa-miR-24-2-5p;hsa-miR-3065-5p;hsa-miR-375;hsa-miR-429;hsa-miR-629-5p | 16 | BCL2 | Sponge network | -3.089 | 2.0E-5 | -3.063 | 1.0E-5 | 0.366 |
7 | RP11-296O14.3 | hsa-miR-141-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-18a-5p;hsa-miR-193a-3p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-200a-3p;hsa-miR-200b-3p;hsa-miR-200c-3p | 12 | PRKACB | Sponge network | -0.987 | 0.02492 | -1.469 | 0.00691 | 0.362 |
8 | RP11-819C21.1 |
hsa-miR-106b-5p;hsa-miR-130a-5p;hsa-miR-149-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-2355-3p;hsa-miR-25-3p;hsa-miR-27a-3p;hsa-miR-590-3p;hsa-miR-7-1-3p;hsa-miR-7-5p;hsa-miR-940 | 12 | XIAP | Sponge network | -1.571 | 0.00379 | 0.212 | 0.49249 | 0.361 |
9 | MAGI2-AS3 |
hsa-let-7a-3p;hsa-let-7f-1-3p;hsa-miR-141-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-18a-5p;hsa-miR-193a-3p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-200a-3p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-2110;hsa-miR-3065-5p;hsa-miR-30d-3p;hsa-miR-362-3p;hsa-miR-429;hsa-miR-590-3p;hsa-miR-93-5p | 21 | PRKACB | Sponge network | -4.563 | 0 | -1.469 | 0.00691 | 0.359 |
10 | AC003090.1 |
hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-320b;hsa-miR-320c;hsa-miR-330-3p;hsa-miR-582-5p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-629-3p | 15 | PIK3R1 | Sponge network | -7.817 | 0.00161 | -1.854 | 0.01274 | 0.358 |
11 | RP11-344E13.3 |
hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-20b-5p;hsa-miR-29b-2-5p;hsa-miR-29b-3p;hsa-miR-93-5p | 10 | AKT3 | Sponge network | -4.307 | 3.0E-5 | -3.327 | 1.0E-5 | 0.355 |
12 | DNM3OS |
hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-142-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-20b-5p;hsa-miR-3065-5p;hsa-miR-502-3p;hsa-miR-93-5p | 11 | AKT3 | Sponge network | -3.933 | 0.00059 | -3.327 | 1.0E-5 | 0.354 |
13 | RP11-819C21.1 |
hsa-miR-15b-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-20a-3p;hsa-miR-21-5p;hsa-miR-24-2-5p;hsa-miR-33b-5p;hsa-miR-629-5p;hsa-miR-7-5p | 10 | BCL2 | Sponge network | -1.571 | 0.00379 | -3.063 | 1.0E-5 | 0.354 |
14 | RP11-774O3.3 |
hsa-miR-15b-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-200a-5p;hsa-miR-200b-5p;hsa-miR-200c-3p;hsa-miR-20a-3p;hsa-miR-21-5p;hsa-miR-215-5p;hsa-miR-24-2-5p;hsa-miR-32-3p;hsa-miR-33b-5p;hsa-miR-365a-3p;hsa-miR-582-5p;hsa-miR-7-5p | 16 | BCL2 | Sponge network | -1.989 | 0.00136 | -3.063 | 1.0E-5 | 0.35 |
15 | HAND2-AS1 |
hsa-miR-15b-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-200a-5p;hsa-miR-200b-3p;hsa-miR-200b-5p;hsa-miR-200c-3p;hsa-miR-20a-3p;hsa-miR-21-5p;hsa-miR-24-2-5p;hsa-miR-32-3p;hsa-miR-33b-5p;hsa-miR-365a-3p;hsa-miR-429;hsa-miR-582-5p;hsa-miR-629-5p;hsa-miR-7-5p | 18 | BCL2 | Sponge network | -7.871 | 0 | -3.063 | 1.0E-5 | 0.35 |
16 | ADAMTS9-AS1 |
hsa-miR-15b-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-200a-5p;hsa-miR-200b-3p;hsa-miR-200b-5p;hsa-miR-200c-3p;hsa-miR-20a-3p;hsa-miR-21-5p;hsa-miR-215-5p;hsa-miR-24-2-5p;hsa-miR-365a-3p;hsa-miR-429;hsa-miR-451a;hsa-miR-582-5p;hsa-miR-590-5p;hsa-miR-629-5p;hsa-miR-7-5p | 19 | BCL2 | Sponge network | -8.573 | 0.00012 | -3.063 | 1.0E-5 | 0.346 |
17 | DNM3OS |
hsa-let-7f-1-3p;hsa-miR-141-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-18a-5p;hsa-miR-193a-3p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-200a-3p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-2110;hsa-miR-3065-5p;hsa-miR-30d-3p;hsa-miR-429;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-93-5p;hsa-miR-96-5p | 21 | PRKACB | Sponge network | -3.933 | 0.00059 | -1.469 | 0.00691 | 0.336 |
18 | HOXB-AS2 | hsa-miR-106b-5p;hsa-miR-130a-5p;hsa-miR-149-5p;hsa-miR-17-5p;hsa-miR-181a-2-3p;hsa-miR-181b-5p;hsa-miR-20a-5p;hsa-miR-2355-3p;hsa-miR-27a-3p;hsa-miR-484 | 10 | XIAP | Sponge network | -0.696 | 0.79824 | 0.212 | 0.49249 | 0.326 |
19 | AC003090.1 |
hsa-miR-15b-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-200a-5p;hsa-miR-200b-5p;hsa-miR-200c-3p;hsa-miR-20a-3p;hsa-miR-21-5p;hsa-miR-24-2-5p;hsa-miR-33b-5p;hsa-miR-365a-3p;hsa-miR-582-5p;hsa-miR-590-5p | 14 | BCL2 | Sponge network | -7.817 | 0.00161 | -3.063 | 1.0E-5 | 0.326 |
20 | HOXA11-AS |
hsa-miR-141-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-18a-5p;hsa-miR-193a-3p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-200a-3p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-2110 | 13 | PRKACB | Sponge network | -3.349 | 0.00194 | -1.469 | 0.00691 | 0.326 |
21 | MIR497HG |
hsa-miR-15b-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-200a-5p;hsa-miR-200b-3p;hsa-miR-200b-5p;hsa-miR-200c-3p;hsa-miR-20a-3p;hsa-miR-21-5p;hsa-miR-24-2-5p;hsa-miR-590-5p;hsa-miR-7-5p | 13 | BCL2 | Sponge network | -6.146 | 0.00024 | -3.063 | 1.0E-5 | 0.322 |
22 | CBR3-AS1 |
hsa-miR-130a-5p;hsa-miR-17-5p;hsa-miR-181a-2-3p;hsa-miR-181b-5p;hsa-miR-19a-3p;hsa-miR-19b-1-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-2355-3p;hsa-miR-27a-3p;hsa-miR-32-3p;hsa-miR-320a;hsa-miR-320b;hsa-miR-335-3p;hsa-miR-484;hsa-miR-589-3p;hsa-miR-766-3p;hsa-miR-940 | 18 | XIAP | Sponge network | 0.742 | 0.15204 | 0.212 | 0.49249 | 0.314 |
23 | RP11-401P9.4 |
hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-142-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-20b-5p;hsa-miR-29b-3p;hsa-miR-502-3p;hsa-miR-93-5p | 10 | AKT3 | Sponge network | -3.793 | 0.00144 | -3.327 | 1.0E-5 | 0.313 |
24 | RAMP2-AS1 | hsa-miR-192-5p;hsa-miR-200b-5p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-215-5p;hsa-miR-24-2-5p;hsa-miR-32-3p;hsa-miR-338-5p;hsa-miR-33b-5p;hsa-miR-365a-3p;hsa-miR-629-5p | 11 | BCL2 | Sponge network | -2.152 | 0.07983 | -3.063 | 1.0E-5 | 0.313 |
25 | RP11-819C21.1 |
hsa-let-7a-3p;hsa-let-7f-1-3p;hsa-miR-141-3p;hsa-miR-16-2-3p;hsa-miR-182-5p;hsa-miR-18a-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-2110;hsa-miR-590-3p;hsa-miR-93-5p | 11 | PRKACB | Sponge network | -1.571 | 0.00379 | -1.469 | 0.00691 | 0.31 |
26 | ACTA2-AS1 |
hsa-miR-106b-5p;hsa-miR-130a-5p;hsa-miR-149-5p;hsa-miR-17-5p;hsa-miR-181a-2-3p;hsa-miR-181b-5p;hsa-miR-19a-3p;hsa-miR-19b-1-5p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-2355-3p;hsa-miR-25-3p;hsa-miR-27a-3p;hsa-miR-33a-3p;hsa-miR-484;hsa-miR-589-3p;hsa-miR-590-3p;hsa-miR-7-5p;hsa-miR-940 | 19 | XIAP | Sponge network | -6.142 | 0.00223 | 0.212 | 0.49249 | 0.308 |
27 | MIR497HG |
hsa-miR-1301-3p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-320c;hsa-miR-584-5p;hsa-miR-590-5p;hsa-miR-629-3p | 13 | PIK3R1 | Sponge network | -6.146 | 0.00024 | -1.854 | 0.01274 | 0.307 |
28 | RP11-119F7.5 | hsa-miR-15b-3p;hsa-miR-16-2-3p;hsa-miR-192-5p;hsa-miR-200a-5p;hsa-miR-200b-3p;hsa-miR-200b-5p;hsa-miR-21-5p;hsa-miR-215-5p;hsa-miR-24-2-5p;hsa-miR-33b-5p | 10 | BCL2 | Sponge network | -2.406 | 0.03687 | -3.063 | 1.0E-5 | 0.307 |
29 | RP11-774O3.3 |
hsa-miR-1271-5p;hsa-miR-18a-3p;hsa-miR-222-5p;hsa-miR-29b-1-5p;hsa-miR-330-3p;hsa-miR-330-5p;hsa-miR-335-3p;hsa-miR-365a-3p;hsa-miR-582-5p;hsa-miR-590-3p | 10 | PIK3R3 | Sponge network | -1.989 | 0.00136 | -0.03 | 0.95933 | 0.305 |
30 | MIR143HG |
hsa-miR-15b-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-192-5p;hsa-miR-200a-5p;hsa-miR-200b-3p;hsa-miR-200b-5p;hsa-miR-200c-3p;hsa-miR-20a-3p;hsa-miR-21-5p;hsa-miR-215-5p;hsa-miR-24-2-5p;hsa-miR-3065-5p;hsa-miR-33b-5p;hsa-miR-429;hsa-miR-451a;hsa-miR-590-5p;hsa-miR-629-5p;hsa-miR-7-5p | 20 | BCL2 | Sponge network | -6.51 | 0 | -3.063 | 1.0E-5 | 0.304 |
31 | NR2F1-AS1 |
hsa-miR-15b-3p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-200c-3p;hsa-miR-20a-3p;hsa-miR-21-5p;hsa-miR-24-2-5p;hsa-miR-33b-5p;hsa-miR-365a-3p;hsa-miR-629-5p;hsa-miR-7-5p | 11 | BCL2 | Sponge network | -2.961 | 0.00154 | -3.063 | 1.0E-5 | 0.303 |
32 | RP11-774O3.3 |
hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-32-3p;hsa-miR-320b;hsa-miR-320c;hsa-miR-330-3p;hsa-miR-335-3p;hsa-miR-582-5p;hsa-miR-590-3p;hsa-miR-629-3p | 16 | PIK3R1 | Sponge network | -1.989 | 0.00136 | -1.854 | 0.01274 | 0.303 |
33 | LINC00865 |
hsa-miR-141-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-18a-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-200a-3p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-2110;hsa-miR-30d-3p;hsa-miR-429 | 14 | PRKACB | Sponge network | -1.585 | 0.19508 | -1.469 | 0.00691 | 0.302 |
34 | CTC-296K1.3 | hsa-let-7f-1-3p;hsa-miR-141-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-18a-5p;hsa-miR-193a-3p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-200a-3p;hsa-miR-2110 | 11 | PRKACB | Sponge network | -6.944 | 0.00011 | -1.469 | 0.00691 | 0.302 |
35 | EPB41L4A-AS1 | hsa-miR-15b-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-200a-5p;hsa-miR-200b-5p;hsa-miR-21-5p;hsa-miR-24-2-5p;hsa-miR-33b-5p;hsa-miR-629-5p | 10 | BCL2 | Sponge network | -2.104 | 0 | -3.063 | 1.0E-5 | 0.3 |
36 | RP11-532F6.3 |
hsa-miR-15b-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-192-5p;hsa-miR-200a-5p;hsa-miR-200b-3p;hsa-miR-200b-5p;hsa-miR-200c-3p;hsa-miR-20a-3p;hsa-miR-24-2-5p;hsa-miR-33b-5p;hsa-miR-451a | 13 | BCL2 | Sponge network | -2.663 | 0.00676 | -3.063 | 1.0E-5 | 0.299 |
37 | ACTA2-AS1 |
hsa-miR-15b-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-200a-5p;hsa-miR-200b-3p;hsa-miR-200b-5p;hsa-miR-200c-3p;hsa-miR-20a-3p;hsa-miR-21-5p;hsa-miR-215-5p;hsa-miR-24-2-5p;hsa-miR-33b-5p;hsa-miR-7-5p | 14 | BCL2 | Sponge network | -6.142 | 0.00223 | -3.063 | 1.0E-5 | 0.298 |
38 | RP11-389C8.2 |
hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-22-5p;hsa-miR-3065-5p;hsa-miR-330-3p;hsa-miR-335-3p;hsa-miR-629-3p | 11 | PIK3R1 | Sponge network | -3.089 | 2.0E-5 | -1.854 | 0.01274 | 0.297 |
39 | MAGI2-AS3 |
hsa-miR-141-3p;hsa-miR-148b-5p;hsa-miR-188-5p;hsa-miR-205-5p;hsa-miR-20a-3p;hsa-miR-324-5p;hsa-miR-421;hsa-miR-429;hsa-miR-501-5p;hsa-miR-590-3p;hsa-miR-660-5p;hsa-miR-9-3p;hsa-miR-92a-3p;hsa-miR-944 | 14 | IRAK3 | Sponge network | -4.563 | 0 | -1.591 | 0.06089 | 0.295 |
40 | RP11-532F6.3 |
hsa-let-7a-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-18a-5p;hsa-miR-193a-3p;hsa-miR-19b-3p;hsa-miR-200b-3p;hsa-miR-200c-3p | 10 | PRKACB | Sponge network | -2.663 | 0.00676 | -1.469 | 0.00691 | 0.295 |
41 | NDUFA6-AS1 |
hsa-miR-18a-3p;hsa-miR-222-5p;hsa-miR-29b-1-5p;hsa-miR-32-5p;hsa-miR-365a-3p;hsa-miR-511-5p;hsa-miR-582-5p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-92a-3p | 10 | PIK3R3 | Sponge network | -1.026 | 0.04234 | -0.03 | 0.95933 | 0.295 |
42 | TRHDE-AS1 |
hsa-miR-15b-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-200a-5p;hsa-miR-200b-3p;hsa-miR-200b-5p;hsa-miR-200c-3p;hsa-miR-20a-3p;hsa-miR-21-5p;hsa-miR-24-2-5p;hsa-miR-32-3p;hsa-miR-33b-5p;hsa-miR-429;hsa-miR-582-5p;hsa-miR-590-5p;hsa-miR-7-5p | 17 | BCL2 | Sponge network | -6.205 | 0.01165 | -3.063 | 1.0E-5 | 0.295 |
43 | FAM66C |
hsa-let-7a-3p;hsa-let-7f-1-3p;hsa-miR-141-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-18a-5p;hsa-miR-193a-3p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-200a-3p;hsa-miR-200b-3p;hsa-miR-2110;hsa-miR-429;hsa-miR-590-3p;hsa-miR-590-5p | 15 | PRKACB | Sponge network | -2.927 | 0.00012 | -1.469 | 0.00691 | 0.294 |
44 | FAM225B | hsa-miR-141-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-18a-5p;hsa-miR-200a-3p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-3065-5p;hsa-miR-590-3p;hsa-miR-93-5p | 12 | PRKACB | Sponge network | -2.388 | 0.00553 | -1.469 | 0.00691 | 0.293 |
45 | MAGI2-AS3 |
hsa-miR-141-3p;hsa-miR-155-5p;hsa-miR-16-2-3p;hsa-miR-182-5p;hsa-miR-186-5p;hsa-miR-200b-3p;hsa-miR-25-3p;hsa-miR-30e-5p;hsa-miR-32-3p;hsa-miR-342-3p;hsa-miR-429;hsa-miR-590-3p | 12 | PRKAR1A | Sponge network | -4.563 | 0 | -1.018 | 0.00123 | 0.292 |
46 | NR2F1-AS1 |
hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-29b-3p;hsa-miR-320b;hsa-miR-330-3p;hsa-miR-590-3p;hsa-miR-629-3p | 12 | PIK3R1 | Sponge network | -2.961 | 0.00154 | -1.854 | 0.01274 | 0.292 |
47 | PSMD5-AS1 |
hsa-miR-15b-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-200c-3p;hsa-miR-20a-3p;hsa-miR-21-5p;hsa-miR-24-2-5p;hsa-miR-590-5p;hsa-miR-629-5p | 10 | BCL2 | Sponge network | -0.973 | 0.02357 | -3.063 | 1.0E-5 | 0.286 |
48 | RP11-567M16.1 |
hsa-miR-1301-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-29b-3p;hsa-miR-320b;hsa-miR-330-3p;hsa-miR-335-3p;hsa-miR-590-5p;hsa-miR-629-3p | 11 | PIK3R1 | Sponge network | -2.638 | 0.21408 | -1.854 | 0.01274 | 0.286 |
49 | DNM3OS |
hsa-miR-1301-3p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-3065-5p;hsa-miR-32-3p;hsa-miR-320b;hsa-miR-320c;hsa-miR-330-3p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-629-3p | 15 | PIK3R1 | Sponge network | -3.933 | 0.00059 | -1.854 | 0.01274 | 0.285 |
50 | FAM66C |
hsa-miR-15b-3p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-200a-5p;hsa-miR-200b-3p;hsa-miR-200b-5p;hsa-miR-20a-3p;hsa-miR-21-5p;hsa-miR-24-2-5p;hsa-miR-33b-5p;hsa-miR-429;hsa-miR-590-5p;hsa-miR-7-5p | 13 | BCL2 | Sponge network | -2.927 | 0.00012 | -3.063 | 1.0E-5 | 0.284 |
51 | RP11-999E24.3 |
hsa-let-7f-1-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-18a-5p;hsa-miR-193a-3p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-2110 | 10 | PRKACB | Sponge network | -4.893 | 2.0E-5 | -1.469 | 0.00691 | 0.284 |
52 | LINC00284 |
hsa-miR-18a-3p;hsa-miR-19b-3p;hsa-miR-222-5p;hsa-miR-29b-1-5p;hsa-miR-330-3p;hsa-miR-330-5p;hsa-miR-365a-3p;hsa-miR-511-5p;hsa-miR-590-3p;hsa-miR-590-5p | 10 | PIK3R3 | Sponge network | -5.478 | 0.02716 | -0.03 | 0.95933 | 0.283 |
53 | RP11-83A24.2 | hsa-miR-130a-5p;hsa-miR-17-5p;hsa-miR-181a-2-3p;hsa-miR-181b-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-20a-5p;hsa-miR-2355-3p;hsa-miR-27a-3p;hsa-miR-335-3p;hsa-miR-484 | 11 | XIAP | Sponge network | -0.473 | 0.33893 | 0.212 | 0.49249 | 0.282 |
54 | RP11-166D19.1 |
hsa-let-7a-3p;hsa-let-7f-1-3p;hsa-miR-141-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-18a-5p;hsa-miR-193a-3p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-200a-3p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-30d-3p;hsa-miR-429;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-96-5p | 19 | PRKACB | Sponge network | -4.209 | 2.0E-5 | -1.469 | 0.00691 | 0.282 |
55 | RP11-774O3.3 |
hsa-let-7a-3p;hsa-let-7f-1-3p;hsa-miR-141-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-18a-5p;hsa-miR-193a-3p;hsa-miR-200c-3p;hsa-miR-2110;hsa-miR-590-3p | 12 | PRKACB | Sponge network | -1.989 | 0.00136 | -1.469 | 0.00691 | 0.28 |
56 | AC003090.1 |
hsa-let-7f-1-3p;hsa-miR-141-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-18a-5p;hsa-miR-193a-3p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-200c-3p;hsa-miR-2110;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-93-5p;hsa-miR-96-5p | 16 | PRKACB | Sponge network | -7.817 | 0.00161 | -1.469 | 0.00691 | 0.279 |
57 | NR2F1-AS1 |
hsa-miR-18a-3p;hsa-miR-19b-3p;hsa-miR-222-5p;hsa-miR-29b-1-5p;hsa-miR-32-5p;hsa-miR-330-3p;hsa-miR-330-5p;hsa-miR-365a-3p;hsa-miR-511-5p;hsa-miR-590-3p;hsa-miR-92a-3p | 11 | PIK3R3 | Sponge network | -2.961 | 0.00154 | -0.03 | 0.95933 | 0.279 |
58 | MAGI2-AS3 |
hsa-miR-15b-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-200a-5p;hsa-miR-200b-3p;hsa-miR-200b-5p;hsa-miR-200c-3p;hsa-miR-20a-3p;hsa-miR-21-5p;hsa-miR-24-2-5p;hsa-miR-3065-5p;hsa-miR-32-3p;hsa-miR-33b-5p;hsa-miR-365a-3p;hsa-miR-429;hsa-miR-629-5p;hsa-miR-7-5p | 18 | BCL2 | Sponge network | -4.563 | 0 | -3.063 | 1.0E-5 | 0.277 |
59 | ZNF667-AS1 |
hsa-miR-15b-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-200c-3p;hsa-miR-20a-3p;hsa-miR-21-5p;hsa-miR-215-5p;hsa-miR-24-2-5p;hsa-miR-590-5p;hsa-miR-629-5p;hsa-miR-7-5p | 12 | BCL2 | Sponge network | -4.019 | 0.00137 | -3.063 | 1.0E-5 | 0.273 |
60 | ZNF667-AS1 |
hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-29b-3p;hsa-miR-320c;hsa-miR-590-5p;hsa-miR-629-3p | 11 | PIK3R1 | Sponge network | -4.019 | 0.00137 | -1.854 | 0.01274 | 0.273 |
61 | RP11-166D19.1 |
hsa-miR-141-3p;hsa-miR-155-5p;hsa-miR-16-2-3p;hsa-miR-182-5p;hsa-miR-186-5p;hsa-miR-200b-3p;hsa-miR-25-3p;hsa-miR-32-3p;hsa-miR-429;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-96-5p | 12 | PRKAR1A | Sponge network | -4.209 | 2.0E-5 | -1.018 | 0.00123 | 0.272 |
62 | HAND2-AS1 |
hsa-let-7a-3p;hsa-let-7f-1-3p;hsa-miR-141-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-18a-5p;hsa-miR-193a-3p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-200a-3p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-2110;hsa-miR-429;hsa-miR-590-3p;hsa-miR-93-5p | 18 | PRKACB | Sponge network | -7.871 | 0 | -1.469 | 0.00691 | 0.272 |
63 | PWAR6 | hsa-miR-15b-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-200b-5p;hsa-miR-20a-3p;hsa-miR-21-5p;hsa-miR-24-2-5p;hsa-miR-33b-5p;hsa-miR-629-5p | 10 | BCL2 | Sponge network | -3.15 | 0.0082 | -3.063 | 1.0E-5 | 0.271 |
64 | AGAP11 |
hsa-miR-106a-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-192-5p;hsa-miR-20b-5p;hsa-miR-215-5p;hsa-miR-301a-3p;hsa-miR-335-3p;hsa-miR-375;hsa-miR-93-5p | 10 | IL1RAP | Sponge network | -2.702 | 0.0073 | 1.813 | 0.02672 | 0.268 |
65 | DNM3OS |
hsa-miR-141-3p;hsa-miR-155-5p;hsa-miR-16-2-3p;hsa-miR-182-5p;hsa-miR-186-5p;hsa-miR-200b-3p;hsa-miR-25-3p;hsa-miR-32-3p;hsa-miR-429;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-96-5p | 12 | PRKAR1A | Sponge network | -3.933 | 0.00059 | -1.018 | 0.00123 | 0.264 |
66 | ACTA2-AS1 |
hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-21-5p;hsa-miR-22-5p;hsa-miR-29b-3p;hsa-miR-590-3p | 10 | PIK3R1 | Sponge network | -6.142 | 0.00223 | -1.854 | 0.01274 | 0.264 |
67 | OR2A1-AS1 | hsa-miR-130a-5p;hsa-miR-149-5p;hsa-miR-17-5p;hsa-miR-181a-2-3p;hsa-miR-181b-5p;hsa-miR-2355-3p;hsa-miR-27a-3p;hsa-miR-320b;hsa-miR-484;hsa-miR-589-3p;hsa-miR-7-5p;hsa-miR-766-3p;hsa-miR-940 | 13 | XIAP | Sponge network | -0.252 | 0.68973 | 0.212 | 0.49249 | 0.263 |
68 | C1RL-AS1 |
hsa-miR-148b-5p;hsa-miR-188-5p;hsa-miR-20a-3p;hsa-miR-3200-3p;hsa-miR-361-5p;hsa-miR-421;hsa-miR-501-5p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-660-5p;hsa-miR-708-3p;hsa-miR-9-3p | 12 | IRAK3 | Sponge network | -0.784 | 0.21481 | -1.591 | 0.06089 | 0.261 |
69 | RP11-999E24.3 |
hsa-miR-15b-3p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-3p;hsa-miR-21-5p;hsa-miR-215-5p;hsa-miR-24-2-5p;hsa-miR-33b-5p;hsa-miR-7-5p | 11 | BCL2 | Sponge network | -4.893 | 2.0E-5 | -3.063 | 1.0E-5 | 0.258 |
70 | TPTEP1 |
hsa-miR-15b-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-200a-5p;hsa-miR-200b-5p;hsa-miR-200c-3p;hsa-miR-20a-3p;hsa-miR-24-2-5p;hsa-miR-33b-5p;hsa-miR-365a-3p;hsa-miR-7-5p | 12 | BCL2 | Sponge network | -4.398 | 5.0E-5 | -3.063 | 1.0E-5 | 0.257 |
71 | MIR143HG |
hsa-let-7f-1-3p;hsa-miR-141-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-18a-5p;hsa-miR-193a-3p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-200a-3p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-2110;hsa-miR-3065-5p;hsa-miR-30d-3p;hsa-miR-429;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-93-5p | 20 | PRKACB | Sponge network | -6.51 | 0 | -1.469 | 0.00691 | 0.253 |
72 | RP11-400K9.4 | hsa-miR-141-3p;hsa-miR-16-2-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-18a-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-200a-3p;hsa-miR-200b-3p;hsa-miR-93-5p | 11 | PRKACB | Sponge network | -0.419 | 0.72905 | -1.469 | 0.00691 | 0.253 |
73 | WT1-AS |
hsa-miR-15b-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-16-5p;hsa-miR-200a-5p;hsa-miR-200b-3p;hsa-miR-200b-5p;hsa-miR-200c-3p;hsa-miR-20a-3p;hsa-miR-24-2-5p;hsa-miR-32-3p;hsa-miR-429;hsa-miR-629-5p | 13 | BCL2 | Sponge network | -6.875 | 2.0E-5 | -3.063 | 1.0E-5 | 0.253 |